JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Genetic Epidemiology of Host Genetic Structure, Viral Persistence, and Immunological Escape in HPV-Mediated Cervical Carcinogenesis

Esther Uyoyooghene Olokede*[1], Jumobi Abeebat Liasu-Thomas[2], Verity Ghansah[3], Bassey Atte Inyang[4], Damilola Rafiat Lamidi[5], Blessing Chinonye Okoro[6], Adebola Ayisat Effa[7]

[1] *Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, University of Benin, Benin City, Edo state, Nigeria*
[2] *Department of Obstetrics and Gynecology, Lagos State University College of Medicine, Lagos, Nigeria*
[3] *Department of Biology, New Mexico Institute of Mining and Technology, New Mexico, USA*
[4] *Department of Medical Biochemistry, College of Health Sciences, University of Abuja, Federal Capital Territory, Nigeria*
[5] *Department of Clinical Sciences, University of Medical Sciences, Ondo, Ondo State, Nigeria*
[6] *Department of Medical Laboratory Science, Imo state University, Owerri, Nigeria*
[7] *Department of Product Development and Quality Assurance, Nigeria Natural Medicine Development Agency, Lagos, Nigeria*

Publication history: Received on 4th February 2026; Revised on 15th March 2026; Accepted on 17th March 2026

Article DOI: 10.69613/d25y8z24

Abstract: Persistent infection with high-risk human papillomavirus genotypes is regarded as the primary etiological driver of cervical neoplasia, yet the vast majority of exposures result in transient subclinical infections that are successfully cleared by host defenses. This biological discrepancy suggests that viral exposure alone is insufficient for oncogenesis, highlighting host genetic susceptibility as a critical mediator of persistence and malignant progression. Inherited variations within the human leukocyte antigen complex, particularly class II loci such as HLA-DRB1 and HLA-DQB1, heavily influence the efficacy of viral antigen presentation and subsequent cell-mediated immune responses. Similarly, polymorphisms in innate immune receptors, cytokine signaling networks, DNA repair mechanisms, and cell cycle checkpoints dictate the microenvironmental conditions that either facilitate viral clearance or permit genomic integration and cellular transformation. In immunocompromised populations, particularly HIV-coinfected cohorts, the pharmacological administration of highly active antiretroviral therapy exerts a profound, though complex, influence on the local microenvironment, altering mucosal CD4+ T-cell reconstitution and modulating viral clearance kinetics. Combining genetic epidemiological data with host-virus interaction models reveals a polygenic architecture of disease risk, modified by both environmental cofactors and viral genomic diversity. Characterization of these host genetic determinants provides a theoretical foundation for refining clinical risk stratification, optimizing therapeutic vaccine interventions, and developing personalized screening algorithms.

Keywords: HPV persistence; Cervical carcinoma; Host genetic susceptibility; Immunogenetics; Human leukocyte antigen; Antiretrovirals.

1. Introduction

Cervical carcinoma is one of the leading causes of cancer-related mortality among women worldwide, particularly within resource-constrained environments [1]. High-risk human papillomavirus genotypes, most notably HPV 16 and 18, are identified as the causative agents in more than 90% of all cases [2]. Although primary preventative measures, such as prophylactic vaccination programs, and secondary screening strategies, including cytological evaluation and high-risk HPV DNA testing, have significantly curtailed disease incidence in high-income countries, global disparities remain stark [3]. The burden of morbidity and mortality is heavily concentrated in low- and middle-income countries, where infrastructural deficits, vaccine hesitancy, and inadequate access to routine screening create systemic barriers to early intervention and treatment [4]. Consequently, cervical neoplasia represents a clear manifestation of global health inequality, requiring both structural public health solutions and a deeper characterization of the biological variations that drive clinical outcomes. The transmission of HPV occurs predominantly via mucosal contact, with a substantial proportion of sexually active individuals acquiring the virus at least once during their lifetime [5]. The clinical timeline of an acquired infection is highly variable. In approximately 80% to 90% of immunocompetent individuals, the immune system successfully clears the viral infection within a period of 12 to 24 months without causing cytological abnormalities or clinical symptoms [6]. This transient state indicates the typical course of infection. Conversely, a distinct subset of infected individuals fails to clear the pathogen, transitioning into a state of chronic, persistent infection. Persistent high-risk HPV infection is the essential

* Corresponding author: Esther Uyoyooghene Olokede

precursor for the sequential development of cervical intraepithelial neoplasia, graded from low-grade lesions (CIN1) to high-grade precancerous lesions (CIN2 and CIN3), which may eventually progress over several decades to invasive squamous cell carcinoma or adenocarcinoma [7]. The observation that only a small fraction of individuals infected with high-risk HPV genotypes progress to high-grade precancerous lesions and invasive malignancies constitutes the fundamental paradox of cervical oncogenesis. This indicates that while high-risk HPV exposure is a necessary cause, it is biologically insufficient to drive carcinogenesis independently [8]. The outcome of an infection is determined by an intricate network of viral, environmental, and host-specific factors. Environmental cofactors, including tobacco use, long-term oral contraceptive usage, multiparity, and concurrent sexually transmitted infections, have been shown to modulate the local cervical microenvironment [9].

The introduction of pharmacological interventions in specific patient cohorts dramatically alters these dynamics. In HIV-positive cohorts, where the risk of HPV persistence and subsequent neoplasia is elevated up to six-fold, the administration of highly active antiretroviral therapy plays a critical pharmacological role [10]. Antiretroviral agents alter the immune landscape by suppressing systemic HIV replication and facilitating the quantitative recovery of $CD4^+$ T-lymphocyte populations, which are vital for local mucosal surveillance [11]. However, the pharmacological impact of highly active antiretroviral therapy on the regression of established cervical lesions remains highly nuanced, as local immunological recovery within the cervical mucosa does not always mirror systemic immune reconstitution. This highlights a complex pharmacological and immunological disconnect that warrants detailed molecular investigation.

Individual variation in host genetic architecture represents a major determinant of susceptibility to persistent HPV infection and subsequent oncogenic transformation. Genetic epidemiology has identified numerous candidate loci that modulate the host immune response and cellular integrity [12]. Polymorphisms within the human leukocyte antigen region on chromosome 6p21.3 are heavily implicated in determining the efficiency of viral peptide presentation to host T-lymphocytes [13]. Beyond major histocompatibility complex loci, single-nucleotide polymorphisms in genes regulating innate immune recognition, such as Toll-like receptors, cytokine signaling cascades, and antiviral interferon pathways, can compromise early mucosal defense systems [14].

Inherited variations in non-immune pathways, particularly those governing genomic stability and cell cycle checkpoints, also influence susceptibility. When the host genome is subjected to the genomic stress imposed by viral oncoproteins, deficiencies in DNA repair genes or cell cycle regulators can accelerate the transition from episomal viral replication to host genomic integration and subsequent cellular transformation [15]. Collectively, these findings indicate that the clinical course of HPV infection is shaped by a highly polygenic host genetic background.

2. Biological Basis of HPV Persistence and Cervical Carcinogenesis

2.1. HPV Life Cycle and Molecular Immune Evasion Mechanisms

The life cycle of the human papillomavirus is strictly dependent on the differentiation program of host stratified squamous epithelial cells. The infectious process begins when viral particles gain access to the proliferating cells of the basal epithelial layer through microscopic abrasions or lesions in the cervical mucosa [16]. Initial binding is mediated by the interaction of the viral capsid protein L1 with heparan sulfate proteoglycans on the basement membrane, followed by internalization via a slow, receptor-mediated endocytic pathway [17]. Upon entry, the double-stranded circular DNA genome of the virus, approximately 8 kilobases in length, is trafficked to the nucleus, where it is maintained as an extrachromosomal element, or episome, at a low copy number of approximately 10 to 100 copies per cell [18].

As the basal cells divide, some daughter cells migrate upward and undergo a highly coordinated process of terminal differentiation. The transcription of viral early genes (E1, E2, E4, E5, E6, and E7) is synchronized with this cellular differentiation program [19]. In the intermediate and superficial layers of the epithelium, vegetative viral DNA replication is initiated, culminating in the expression of the late capsid proteins L1 and L2, virion assembly, and non-lytic shedding into the environment [20].

To maintain this productive cycle over extended periods, HPV has evolved sophisticated strategies to evade both the innate and adaptive arms of the host immune system. The virus restricts its life cycle entirely to the intraepithelial compartment, avoiding the vascular circulation and thereby preventing systemic inflammatory responses, viremia, and cell lysis [21]. This absence of physical cellular damage minimizes the recruitment of antigen-presenting cells, such as Langerhans cells and dermal dendritic cells, to the site of infection. At the molecular level, the viral early proteins E6 and E7 actively suppress the expression of major histocompatibility complex class I molecules, thereby directly impairing the ability of cytotoxic T-lymphocytes to recognize and destroy infected cells [22]. Additionally, these oncoproteins interfere with the intracellular transcription of interferon-stimulated genes by binding to interferon regulatory factors, effectively neutralizing the cell-intrinsic antiviral state [23]. This silent replication profile allows the virus to persist within the mucosal tissue, establishing a chronic infectious state that serves as the foundation for subsequent malignant transformation.



Figure 1. Epithelial entry, vegetative cycles, and oncogenic genome integration pathways of high-risk HPV.

Basal cell infection requires exposure of the basement membrane matrix via mechanical microabrasions. In the absence of trauma, intact physical mucin systems and desmosomal cellular complexes clear or block viral entry

2.2. Neoplastic Transition and Cellular Transformation Pathways

The progression of a persistent high-risk HPV infection to clinical malignancy is characterized by a series of well-defined molecular and cellular events. This neoplastic transition is driven by the sustained, unregulated intracellular expression of the viral oncoproteins E6 and E7 [24]. Under normal episomal conditions, the transcription of these oncoproteins is tightly controlled by the viral regulatory protein E2, which acts as a transcriptional repressor by binding to specific promoter elements [25]. However, persistent cellular stress and genomic instability frequently lead to the integration of the circular viral genome into the host chromosome.

During the process of integration, the viral DNA molecule is cleaved, which typically results in the deletion or disruption of the open reading frame of the E2 gene [26]. The loss of functional E2 expression relieves the transcriptional repression on the E6 and E7 promoters, leading to the continuous, high-level synthesis of these oncoproteins within the host cell. The overexpressed E6 and E7 oncoproteins target critical cellular tumor suppressor pathways to bypass normal regulatory checkpoints. The E6 protein binds directly to a host cellular ubiquitin ligase known as E6-associated protein (E6AP) [27]. The resulting heterodimeric complex recruits the tumor suppressor protein p53, facilitating its polyubiquitination and subsequent rapid degradation via the 26S proteasome pathway. Under physiological conditions, p53 is activated in response to DNA damage, driving cell cycle arrest at the G1/S transition through the upregulation of the cyclin-dependent kinase inhibitor p21, or initiating programmed cell death (apoptosis) if the genetic lesions are irreparable [28]. The E6-mediated depletion of p53 deprives the cell of this critical genomic safeguard, allowing cells with damaged DNA to replicate unchecked.

Concurrently, the E7 oncoprotein targets the retinoblastoma protein (pRb) family of tumor suppressors [29]. E7 binds to pRb via its highly conserved LXCXE motif, promoting its phosphorylation and targeting it for proteasomal degradation. This action disrupts the physiological complex between pRb and the E2F family of transcription factors. The release of free E2F transcription factors activates the transcription of genes required for entry into the S-phase of the cell cycle, such as cyclin E and cyclin A, forcing the cell into unrestricted DNA synthesis independent of external growth-regulatory signals [30]. The synergy between p53 degradation by E6 and pRb inactivation by E7 leads to a rapid accumulation of chromosomal abnormalities, telomere dysfunction, and genomic instability, driving the clonal evolution of the cell toward an invasive phenotype.

2.3. Host–Virus Microenvironmental Dynamics

The clinical outcome of an HPV infection whether it is successfully resolved or advances toward malignancy depends on the immunological microenvironment of the uterine cervix. The local mucosal immune system must execute a coordinated cascade of events involving cellular recruitment, cytokine signaling, and antigen presentation [31]. The initial detection of viral components is mediated by pattern recognition receptors, such as Toll-like receptors (TLR3 and TLR9), expressed on local epithelial cells and resident antigen-presenting cells [32].

Upon activation, these receptors trigger downstream intracellular signaling pathways, inducing the transcription of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and type I interferons (IFN-α and IFN-beta) [33]. These

chemical signals recruit innate immune effector cells, including natural killer cells, dermal dendritic cells, and macrophages, to the localized site of infection.

The ultimate clearance of the virus is highly dependent on the generation of a robust, antigen-specific adaptive cell-mediated immune response. Professional antigen-presenting cells must internalize viral proteins, process them into immunogenic peptides, and traffic to regional lymph nodes to prime naive helper T-lymphocytes ($CD4^+$) and cytotoxic T-lymphocytes ($CD8^+$) [34]. This process requires a Helper T type 1 (Th1) polarized cytokine milieu, characterized by high local concentrations of interleukin-12 (IL-12) and interferon-gamma (IFN-γ) [35].

However, persistent HPV infection actively subverts this microenvironment. The continuous expression of the viral oncoproteins alters the local cellular secretome, suppressing the production of the chemokine CCL20, which in turn limits the chemotactic recruitment of Langerhans cells to the epithelial lesions [36]. The microenvironment is shifted from a protective, pro-inflammatory Th1 profile toward a highly immunosuppressive and tolerogenic state, characterized by elevated levels of transforming growth factor-beta (TGF-beta) and interleukin-10 (IL-10) [37]. This regulatory phenotype impairs the cytotoxic activity of $CD8^+$ T-lymphocytes and natural killer cells, preventing the destruction of the infected epithelial cells and facilitating chronic, long-term persistence.

2.4. Antiretroviral Pharmacology and Viral Persistence in Immunocompromised Cohorts

In HIV-positive populations, the biological dynamics of HPV persistence are severely altered. The progressive systemic depletion of $CD4^+$ T-lymphocytes caused by HIV infection directly translates to a profound impairment of mucosal immune surveillance in the female reproductive tract [38]. The local cervical microenvironment in HIV-coinfected individuals is marked by chronic mucosal inflammation, altered epithelial barrier integrity, and diminished cytotoxic lymphocyte function, which dramatically increases susceptibility to persistent high-risk HPV and accelerated neoplastic progression [39].

The introduction of Highly Active Antiretroviral Therapy (HAART) has revolutionized the clinical management of HIV, but its specific pharmacological relationship with HPV clearance is complex. The primary mechanism of action of antiretroviral regimens consisting of combinations of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs) is the robust suppression of systemic HIV replication and the subsequent recovery of CD4+ T-cell counts [40].



Figure 2. Pharmacological impact of Highly Active Antiretroviral Therapy (HAART) on mucosal immunology and HPV clearance kinetics in HIV-positive cohorts.

Under untreated HIV co-infection, severe systemic and local $CD4^+$ T-cell depletion destroys mucosal surveillance, accelerating disease progression. The administration of systemic HAART suppresses HIV viral loads and recovers systemic T-cell subsets, facilitating the immunological clearance of newly acquired high-risk HPV. However, established, integrated high-grade lesions (CIN2/3) frequently persist due to localized immune exhaustion, demonstrating the compartmentalized nature of mucosal immune reconstitution

At the tissue level, pharmacological reconstitution of the immune system by HAART partially restores local mucosal cellular immunity. Successful suppression of HIV viral load reduces the local production of HIV-1 Tat protein, which has been shown to synergize with HPV oncoproteins to promote angiogenesis and cell proliferation [41]. Under the influence of stable HAART, the

recovery of mucosal $CD4^+$ Th1 cells enhances the secretion of IFN-γ and IL-12, thereby promoting the clearance of newly acquired high-risk HPV infections and reducing the overall rate of incident HPV acquisition [42].

Despite these systemic benefits, clinical observations indicate that the pharmacological administration of HAART does not lead to a uniform or immediate clearance of established high-grade pre-existing cervical lesions (CIN2/3). This clinical phenomenon points to a persistent localized immune exhaustion within the cervical microenvironment. Even when systemic $CD4^+$ T-lymphocyte counts normalize, the local tissue microenvironment may remain immunologically compromised due to the persistent down-regulation of Toll-like receptors and the presence of regulatory T-cells (Tregs) that secrete immunosuppressive cytokines [43].

Specific classes of antiretroviral agents may exert direct, off-target pharmacological effects on the cervical epithelium. For instance, certain HIV protease inhibitors, such as lopinavir and ritonavir, have been investigated for their capacity to directly inhibit human proteasomes, potentially altering the degradation kinetics of the E6-mediated p53 target within dysplastic cells [44]. This highlights a biological intersection where the pharmacological properties of systemic antiretrovirals modulate the localized oncogenic progression of HPV.

3. Genetic Epidemiology of HPV Susceptibility

3.1. Pathological Stages

Genetic epidemiology uses quantitative and genetic tools to evaluate how inherited genomic variations contribute to disease distribution and susceptibility across human populations. When applied to the natural history of the human papillomavirus, this scientific discipline seeks to dissect the complex host genetic architecture that governs the transition between distinct pathological stages of infection [45].

The primary clinical error in early epidemiological analyses was treating HPV-related cervical neoplasia as a single, homogenous disease process. Modern genetic epidemiology conceptualizes this pathway as a series of biologically distinct steps, each regulated by different host genetic loci:

The first phase is viral acquisition, which is primarily determined by behavioral exposures, mucosal barrier integrity, and the baseline expression of cell surface receptors [46]. The second phase is the persistence of the viral infection, defined in longitudinal clinical cohorts as the detection of the identical high-risk HPV genotype at two or more consecutive clinic visits at least 6 or 12 months apart [47]. Genetic variants in immune recognition and inflammatory clearance are key regulators of this stage.

The final phase is neoplastic progression, characterized by the accumulation of somatic mutations, chromosomal alterations, and genomic instability. This stage is influenced by inherited genetic variations in cell cycle checkpoints and DNA repair complexes [48]. Genetic epidemiologists can identify stage-specific susceptibility alleles by distinguishing between these stages, improving the precision of genetic risk prediction models.

3.2. Methodological Approaches in Genetic Association

The identification of specific genetic variants associated with susceptibility to HPV persistence and cervical neoplasia has evolved through several methodological phases. Early genetic association studies utilized the candidate gene design, which selects specific polymorphic loci based on a prior physiological hypothesis regarding their function [49]. This approach typically focused on genes of the immune system, such as specific human leukocyte antigen class I and II alleles, or cytokines like interleukin-10 (IL-10) and tumor necrosis factor-alpha (TNF-α).

While candidate gene studies successfully identified several critical susceptibility loci, they have been historically limited by small sample sizes, a lack of independent replication across ancestral populations, and a susceptibility to false-positive findings due to uncontrolled confounding factors like population stratification [50].

To overcome these biological and statistical limitations, the field has transitioned to hypothesis-free Genome-Wide Association Studies (GWAS). This approach allows for the simultaneous scanning of millions of single-nucleotide polymorphisms across the entire genome, identifying novel loci without requiring prior functional assumptions [51]. Modern GWAS designs require large, well-characterized clinical cohorts to achieve sufficient statistical power to detect alleles with small effect sizes, typically using a strict Bonferroni-corrected significance threshold of $\alpha = 5 \text{ times } 10^{-8}$ [52].

Additionally, these studies utilize advanced statistical techniques, such as principal component analysis, to correct for ancestral population stratification. Longitudinal cohort studies, which monitor patients over time, provide the most robust clinical

phenotyping for GWAS of HPV persistence, as they allow researchers to clearly distinguish between individuals who spontaneously clear the infection and those who exhibit true, long-term persistent states [53].

3.3. Epidemiological Variations and Hereditary Estimates

Evidence of a host genetic basis for cervical cancer susceptibility is supported by classic quantitative genetic studies. Heritability estimates derived from large-scale, population-based twin registries and multi-generational family studies indicate that the host genetic contribution to the liability of developing cervical carcinoma is approximately 27% to 29%, with the remaining variance attributed to environmental exposures and stochastic viral events [54]. This substantial heritable component shows that host genetics is a major driver of clinical outcomes.

However, the distribution of these genetic risk factors is highly heterogeneous across global populations. Allele frequencies for key susceptibility loci, particularly within the highly polymorphic human leukocyte antigen complex, exhibit dramatic variations across different geographic ancestries [55]. For example, a protective HLA allele that is highly prevalent in populations of northern European descent may be virtually absent in sub-Saharan African cohorts, where the cervical cancer burden is highest.

This ancestral divergence highlights a major limitation in the existing genetic literature: the vast majority of large-scale GWAS and epidemiological analyses have been conducted in cohorts of European and East Asian ancestry, severely limiting the generalizability of their findings [56]. To address these global health disparities, genetic epidemiologists must actively recruit and analyze diverse, ancestrally heterogeneous cohorts, ensuring that emerging clinical tools such as polygenic risk scores are equitable and effective for all populations.

4. Host Immune Genetic Determinants

4.1. Human Leukocyte Antigen (HLA) Polymorphisms

4.1.1. HLA Class I Alleles and Cytotoxic T-Cell Surveillance

The elimination of human papillomavirus-infected keratinocytes is heavily dependent on the presentation of intracellularly derived viral peptides on the surface of host cells. This presentation is mediated by human leukocyte antigen (HLA) class I molecules, which are encoded by the highly polymorphic classical loci HLA-A, HLA-B, and HLA-C on chromosome 6p21.3 [57]. Under physiological conditions, newly synthesized viral proteins within the host cell cytoplasm, such as the early proteins E6 and E7, are targeted for degradation by the immunoproteasome. The resulting peptide fragments, typically 8 to 10 amino acids in length, are transported across the membrane of the endoplasmic reticulum by the transporter associated with antigen processing (TAP1 and TAP2) complex [58]. Within the lumen of the endoplasmic reticulum, these peptides are loaded into the peptide-binding grooves of nascent HLA class I heavy chains stabilized by beta-2-microglobulin (B2M).

Specific allelic variations in the HLA class I peptide-binding groove alter the electrostatic charge and spatial conformation of the binding pockets, directly dictating the affinity for immunodominant high-risk human papillomavirus peptides [59]. For instance, certain HLA-B alleles possess peptide-binding grooves with hydrophobic or charged residues at critical anchor pockets, such as pocket 2 and pocket 9, which facilitate high-affinity binding of E6 and E7 epitopes. This high-affinity binding promotes stable cell-surface presentation, leading to robust recognition and activation of $CD8^+$ cytotoxic T-lymphocytes [60].

Conversely, other alleles, including specific variants within the HLA-A*02 supertype, may present low binding affinities for oncogenic viral peptides, resulting in weak or transient cell-surface presentation. This weak presentation allows infected cells to escape immunological surveillance. The capacity of high-risk human papillomavirus oncoproteins to actively downregulate the transcription of classical HLA class I genes through epigenetic silencing and transport interference further accentuates the biological impact of inherited host genetic variations in these loci [61].

4.1.2. HLA Class II Loci and CD4+ Helper T-Cell Activation

While HLA class I molecules are critical for cell-mediated cytotoxicity, the orchestration of a sustained, long-term cellular immune response requires the activation of $CD4^+$ helper T-lymphocytes. This activation is mediated by classical HLA class II molecules, which are encoded by the HLA-DR, HLA-DQ, and HLA-DP gene complexes [62]. These heterodimeric transmembrane glycoproteins are selectively expressed on professional antigen-presenting cells, such as Langerhans cells, macrophages, and dendritic cells, which infiltrate the cervical epithelium during active viral replication.

Genetic epidemiological investigations have consistently identified robust associations between specific HLA class II alleles and the risk of persistent human papillomavirus infection and progression to cervical neoplasia [63]. The most frequently replicated risk

factor across diverse geographical populations is the HLA-DRB1*15:01 allele, which is in strong linkage disequilibrium with the HLA-DQB1*06:02 allele. Structural modeling of the HLA-DRB1*15:01 protein shows that its peptide-binding pocket contains unique amino acid substitutions that alter the presentation of human papillomavirus L1 capsid peptides, reducing the activation of $CD4^+$ helper T-cells and leading to a failure of viral clearance [64].

In contrast, other HLA class II alleles, such as HLA-DRB1*13:01 and HLA-DQB1*06:03, have been consistently associated with protection against persistent infection and cervical carcinoma. The protective effect of these alleles is attributed to their capability to bind and present highly conserved E6 or E7 epitopes with superior binding dynamics, inducing a strong Helper T type 1 (Th1) immune response characterized by the secretion of pro-inflammatory cytokines that facilitate mucosal clearance [65].

The structural variations in the peptide-binding pockets of these alleles, specifically within the polymorphic beta-chain variable domains, determine the immunological fate of the host upon encounter with high-risk viral genotypes. This highlights the central role of HLA class II architecture in modulating susceptibility to persistent oncogenic infection.

4.1.3. Epistatic Interactions and Haplotype-Specific Susceptibility

The genetic architecture of the major histocompatibility complex is characterized by exceptional density and extensive linkage disequilibrium, which means that individual alleles are rarely inherited in isolation. Instead, they are transmitted as coordinated haplotypic blocks. Epidemiological investigations have shown that the association of HLA alleles with human papillomavirus persistence is often modified by epistatic interactions non-additive genetic interactions where the phenotypic manifestation of one locus is dependent on the genetic background at another locus [66].

Table 1. HLA Class I and II Immunogenetic Profiles and HPV Clinical Phenotypes

HLA Class / Locus	Specific Allele / Haplotype	Clinical Association	Molecular Mechanism	References
Class II (HLA-DR)	HLA-DRB1*15:01	Highly elevated risk of persistent infection and invasive squamous cell carcinoma	Amino acid substitutions in the polymorphic β-chain variable domains alter the electrostatic charge of the peptide-binding pocket, reducing binding affinity for immunodominant L1 capsid peptides and impairing helper T-cell priming.	[63], [64]
Class II (HLA-DQ)	HLA-DQB1*06:02	Strong risk factor for high-grade cervical intraepithelial neoplasia (CIN2/3)	Inherited in strong linkage disequilibrium with DRB1*15:01; results in poor presentation of E6 and E7 epitopes, leading to a failure of antigen-specific $CD4^+$ Th1 immune activation.	[64], [67]
Class II (HLA-DR)	HLA-DRB1*13:01	Consistent protection against persistent high-risk HPV infection	Exhibits superior binding dynamics for conserved viral capsid and early proteins, coordinating a robust Th1 cytokine response characterized by high mucosal levels of IFN-γ.	[65]
Class II (HLA-DQ)	HLA-DQB1*06:03	Protective against progression to invasive carcinoma	Efficiently processes and presents E7 epitopes, maintaining active mucosal surveillance and promoting cytotoxic T-lymphocyte ($CD8^+$) recruitment.	[65]
Class I (HLA-B)	HLA-B*07	Elevated risk of oncogenic transition (epistatic with DR15)	Possesses hydrophobic residues in anchor pocket 9 that favor low-affinity binding of viral peptide fragments, allowing infected basal cells to escape $CD8^+$ cytotoxic T-cell surveillance.	[60], [67]
Class I (HLA-C)	HLA-Cw*15	Modulated risk of cervical adenocarcinoma	Selective HLA-C presentation dynamics alter natural killer (NK) cell inhibition via KIR interactions, preventing early innate-mediated cytolysis of infected basal cells.	[68]

For example, the presence of the susceptible HLA-DRB1*15:01 allele significantly increases the risk of cervical carcinogenesis when co-inherited with specific alleles of the classical class I locus HLA-B*07. This haplotype-specific synergy suggests that the concurrent failure of both $CD4^+$ helper T-cell priming and $CD8^+$ cytotoxic T-cell surveillance creates an immunological blind spot, enabling uninterrupted viral replication and genomic integration [67].

Epistatic interactions extend beyond classical HLA genes to encompass non-classical histocompatibility complexes and immune checkpoint regulators located within the major histocompatibility complex region. Polymorphic variations in the cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1) genes have been shown to modulate the strength of HLA-mediated T-cell activation.

In individuals carrying the high-risk DR15-DQ6 haplotype, co-inheritance of promoter polymorphisms that upregulate CTLA4 or PDCD1 expression can suppress the residual cell-mediated immune response, driving mucosal immune exhaustion [68]. Deciphering these complex multi-locus genetic interactions is essential for building accurate predictive models of genetic susceptibility. This complex genomic landscape highlights the limitation of single-gene association analyses in capturing the complete picture of host-virus immunogenetics.

4.2. Cytokine Signaling Networks and Immunomodulation

4.2.1. Pro-inflammatory Cytokine Cascades (TNF-alpha and IL-6)

Cytokines serve as the molecular messengers of the immune system, regulating the recruitment, activation, and differentiation of immune cells within the cervical microenvironment. Single-nucleotide polymorphisms in genes encoding pro-inflammatory cytokines can disrupt this regulatory network, compromising the host's capacity to clear active infections [69]. Tumor necrosis factor-alpha (TNF-α), encoded by the TNF gene on chromosome 6p21.3, is a pleiotropic cytokine that induces apoptosis in virus-infected and transformed epithelial cells.

The TNF promoter polymorphism -308G>A (rs1800629) has been widely evaluated in genetic epidemiological studies. The variant A allele is associated with elevated transcriptional activity and increased production of TNF-α. While higher TNF-α levels would theoretically favor viral clearance, chronic local overproduction of this cytokine can promote tissue inflammation, extracellular matrix remodeling, and angiogenesis, accelerating the progression of cervical lesions [70].

Similarly, interleukin-6 (IL-6) is an important pro-inflammatory cytokine that regulates cell growth, differentiation, and the transition from acute to chronic inflammation. Polymorphisms in the promoter region of the IL-6 gene, such as -174G>C (rs1800795), modulate the level of IL-6 expression in response to cellular stress. In individuals carrying the high-producing G allele, elevated IL-6 levels stimulate downstream signal transducer and activator of transcription 3 (STAT3) signaling pathways in cervical epithelial cells [71].

The activation of STAT3 upregulates the transcription of anti-apoptotic genes such as BCL2 and BCLXL, counteracting the apoptosis-inducing signals of the host and promoting the survival of cells expressing the viral oncoproteins E6 and E7. This shows how inherited variations in pro-inflammatory cytokine signaling pathways can alter the local microenvironment, transforming it into a setting that supports cell survival and oncogenesis.

4.2.2. Immunosuppressive Cytokines (IL-10 and TGF-beta)

In contrast to pro-inflammatory signaling cascades, immunosuppressive cytokines act to limit inflammatory responses and promote immunological tolerance. However, within the context of chronic viral infections, hyper-activation of these immunosuppressive pathways can prevent effective viral clearance. Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine that inhibits the synthesis of pro-inflammatory cytokines and suppresses the antigen-presenting capacity of dendritic cells [72].

The promoter of the IL-10 gene exhibits several highly conserved single-nucleotide polymorphisms, including -1082G>A (rs1800896), -819C>T (rs1800871), and -592C>A (rs1800872), which are inherited as distinct haplotypes (such as GCC, ACC, and ATA). The low-producing ATA haplotype is associated with decreased IL-10 secretion, which correlates with enhanced viral clearance and a lower risk of cervical carcinogenesis [73].

Conversely, individuals carrying high-producing IL-10 haplotypes exhibit a suppressed local mucosal immune response, characterized by reduced recruitment of Th1 cells and decreased expression of costimulatory molecules on Langerhans cells. This suppression is further compounded by genetic variations in the transforming growth factor-beta (TGF-beta) pathway.

TGF-beta is a multi-functional cytokine that regulates immune suppression, epithelial-to-mesenchymal transition, and tissue remodeling. Polymorphisms in the TGFB1 gene, such as the codon 10T>C (rs1800469) transition, alter the secretion levels of active TGF-beta within the cervical stroma [74]. Elevated levels of local TGF-beta suppress the proliferation and cytotoxic function of both $CD8^+$ T-cells and natural killer cells, creating a protective, tolerogenic niche that facilitates the long-term persistence of high-risk human papillomavirus genotypes.

4.2.3. Genetic Variations in Cytokine Receptor Pathways

The functional outcome of cytokine signaling is determined not only by ligand concentration but also by the expression and signaling efficiency of their corresponding transmembrane receptors. Genetic polymorphisms within cytokine receptor genes can alter binding affinity, receptor stability, or downstream signal transduction cascades.

The interleukin-12 receptor beta 1 (IL12RB1) gene, which encodes a critical component of the receptor complex for both IL-12 and IL-23, is highly polymorphic. Interleukin-12 signaling is essential for the differentiation of naive T-cells into interferon-gamma-secreting Th1 cells [75]. Polymorphisms that compromise IL12RB1 receptor function impair Th1 cell-mediated immunity, leading to a deficiency in interferon-gamma production and a subsequent failure to eliminate virus-infected keratinocytes.

Additionally, genetic variations in the receptors for chemokines, which direct the migration of immune cells to sites of infection, play an important role. The chemokine receptor CCR5 and its ligand CCL5 (RANTES) are critical for the trafficking of activated T-lymphocytes and macrophages into the cervical mucosa.

A well-characterized 32-base-pair deletion in the CCR5 gene (CCR5-Delta32, rs333) results in a non-functional, truncated receptor that fails to localize to the cell membrane [76]. Homozygous or heterozygous carriers of this deletion exhibit significantly impaired recruitment of cytotoxic $CD8^+$ T-lymphocytes to the cervical epithelium, creating a localized immune deficit that facilitates viral persistence and progression to high-grade intraepithelial lesions. This highlights how genetic variation at multiple levels of the cytokine-chemokine receptor axis can undermine mucosal immune defenses.

4.3. Innate Pattern Recognition and Early Host Response

4.3.1. Toll-Like Receptor 3 and 9 Polymorphisms

The initiation of an effective immune response against human papillomavirus depends on the rapid detection of viral pathogen-associated molecular patterns by host pattern recognition receptors. Toll-like receptors (TLRs) are the primary sensors of viral infection in the cervical epithelium. Toll-like receptor 3 (TLR3), located in endosomal membranes, recognizes double-stranded RNA intermediates generated during viral transcription, while Toll-like receptor 9 (TLR9) detects unmethylated cytidine-phosphate-guanosine (CpG) DNA motifs present in the viral genome [77].

Polymorphic variations in these receptor genes can impair their ligand-binding affinity or cellular localization, compromising early immunological detection. In the TLR9 gene, the promoter polymorphism -1486T>C (rs5743836) and the synonymous coding variant 2848C>T (rs352140) have been identified as key genetic determinants of susceptibility. The -1486C allele disrupts a putative transcription factor binding site, leading to a down-regulation of TLR9 expression in cervical keratinocytes [78].

This diminished expression of TLR9 leads to a failure in sensing viral replication, reducing the activation of downstream signaling networks and the subsequent transcription of type I interferons. Similarly, single-nucleotide polymorphisms in the TLR3 gene, such as the coding variant rs3775291 (Phe412Leu), alter the structural stability of the extracellular domain of the receptor.

This structural alteration reduces its binding affinity for viral nucleic acids, impairing the induction of the cell-intrinsic antiviral response and allowing the virus to establish a persistent replication cycle in the basal keratinocytes without triggering cellular alarm systems [79]. This failure of early detection is a critical step in the transition from an acute, transient infection to a chronic, high-risk persistent state.

4.3.2. Downstream Signaling Intermediates (MYD88 and TRIF)

Upon ligand binding, Toll-like receptors undergo conformational changes that recruit specific intracellular adapter proteins to initiate downstream signaling. TLR9 signals through the myeloid differentiation primary response gene 88 (MyD88) adapter protein, whereas TLR3 utilizes the TIR-domain-containing adapter-inducing interferon-beta (TRIF, encoded by TICAM1) pathway [80].

Genetic variations within these adapter proteins and their associated downstream kinases can impair the signal transmission process. Polymorphisms in the MYD88 promoter or coding regions can reduce the stability of the MyD88 signaling complex, preventing the recruitment of interleukin-1 receptor-associated kinases (IRAK1 and IRAK4). This impairment suppresses the downstream activation of the I-kappa-B kinase (IKK) complex, limiting the nuclear translocation of the transcription factor nuclear factor-kappa-light-chain-enhancer of activated B cells (NF-kappa B) [81].

Table 2. Innate Pattern Recognition and Cytokine Polymorphisms Modulating Clearance Kinetics

Gene Target	SNP ID (rsID)	Allelic Variant	Functional Consequence	Immunological Impact on HPV Clearance	References
TLR9	rs5743836	-1486T>C	Promotes down-regulation of Toll-like receptor 9 transcriptional expression in local cervical keratinocytes.	Compromises the sensing of unmethylated viral CpG DNA motifs, delaying the activation of downstream MyD88-dependent signaling cascades.	[77], [78]
TLR3	rs3775291	Phe412Leu	Alters the spatial conformation and structural stability of the endosomal receptor's extracellular ligand-binding domain.	Restricts the binding affinity for double-stranded RNA intermediates generated during vegetative viral transcription, suppressing cell-intrinsic antiviral pathways.	[79]
TNF	rs1800629	-308G>A	Elevates transcriptional activity, leading to local overproduction of tumor necrosis factor-alpha (TNF-α).	Promotes chronic mucosal tissue inflammation, extracellular matrix remodeling, and localized angiogenesis within the transformation zone.	[69], [70]
IL10	rs1800896	-1082G>A	Haplotype-specific variations (GCC vs. ATA) dictate high vs. low systemic expression levels of Interleukin-10.	High-producing GCC carriers exhibit a highly tolerogenic cervical microenvironment, characterized by suppressed Langerhans cell costimulatory function.	[72], [73]
CCR5	rs333	Δ32 (deletion)	Yields a non-functional, truncated chemokine receptor that fails to localize to the host cell membrane.	Impairs the chemotactic recruitment of cytotoxic $CD8^+$ T-lymphocytes and macrophages into the cervical mucosa during active infection.	[76]
OAS1	rs11314454	Splice-site variant	Alters the alternative splicing and baseline enzymatic activity of the 2'-5'-oligoadenylate synthetase 1 protein.	Diminishes the degradation rate of viral transcripts by the RNaseL pathway, facilitating unchecked episomal replication.	[80]



Figure 3. Intracellular innate pattern recognition and downstream interferon signal transduction networks.

Left: The endosomal sensing of unmethylated viral CpG motifs by TLR9. Successful receptor dimerization recruits the MyD88-dependent signalosome, phosphorylating I-kappa-B kinases (IKK) and activating NF-κB translocation. Inherited single-nucleotide polymorphisms in the promoter of TLR9 or downstream adapter genes cause signaling blocks, facilitating silent replication. Right: Type I/III interferon signaling transduction kinetics. Dimerization activates JAK1/TYK2, phosphorylating STAT1/STAT2 to recruit IRF9, forming the ISGF3 transcription factor complex. This complex translocates into the nucleus to bind interferon-stimulated response elements (ISREs).

The failure of NF-kappa B nuclear translocation impairs the transcription of pro-inflammatory cytokines, preventing the recruitment and activation of local professional antigen-presenting cells. Similarly, polymorphisms in the TICAM1 gene can alter the assembly of the TRIF signalosome, compromising the activation of TANK-binding kinase 1 (TBK1) and the downstream phosphorylation of interferon regulatory factors [82].

This pathway-specific signaling block prevents the timely induction of an antiviral state in adjacent uninfected keratinocytes, facilitating the localized spread of viral particles across the cervical transformation zone. These findings indicate that host genetic variations in the intracellular signal transduction machinery can lead to a state of localized immunodeficiency, even in the presence of functional receptor systems.

4.3.3. Natural Killer Cell Activation and Killer Cell Immunoglobulin-Like Receptors

Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that play a key role in the rapid elimination of virus-infected and transformed cells. Their activation is regulated by a balance of signals received through activating and inhibitory receptors, including the highly polymorphic killer cell immunoglobulin-like receptor (KIR) family [83]. KIR receptors interact with classical HLA class I molecules expressed on target cells.

The genes encoding KIRs and their HLA ligands are located on different chromosomes (chromosomes 19 and 6, respectively), and their co-inheritance creates highly variable receptor-ligand combinations across individuals. Inhibitory KIRs, such as KIR2DL1 and KIR2DL3, recognize specific HLA-C allotypes (C1 and C2 groups), sending inhibitory signals that prevent NK cell activation and spare healthy cells expressing normal HLA levels [84].

However, high-risk human papillomavirus genotypes often downregulate classical HLA-A and HLA-B molecules while selectively sparing HLA-C expression to evade T-cell recognition without triggering NK cell-mediated lysis. Genetic epidemiological studies have showed that the presence of specific activating KIR genes, such as KIR2DS4 or KIR3DS1, is associated with an increased capacity to clear human papillomavirus infections and a reduced risk of cervical carcinoma [85].

These activating receptors can bind to upregulated stress ligands on infected keratinocytes, overriding inhibitory signals and triggering NK cell-mediated cytolysis. Conversely, individuals who possess a genetic profile dominated by inhibitory KIR genes and their corresponding HLA-C ligands are susceptible to persistent infection, as their NK cells remain functionally suppressed in the presence of virus-infected epithelial cells. This highlights the importance of the innate immunogenetic profile in determining the early outcome of viral exposure.

4.4. Antiviral Interferon Signaling Pathways

4.4.1. Type I and Type III Interferon Signaling Kinetics

The interferon system constitutes the primary cell-intrinsic defense barrier against viral pathogens. Type I interferons (IFN-α and IFN-beta) and Type III interferons (IFN-lambda1, IFN-lambda2, IFN-lambda3, and IFN-lambda4) are produced by infected keratinocytes and immune cells upon the detection of viral nucleic acids [86]. These ligands bind to their respective heterodimeric receptors on the cell surface the Type I interferon receptor (IFNAR1/IFNAR2) complex and the Type III interferon receptor (IFNLR1/IL10RB) complex triggering the canonical Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway.

This intracellular signal cascade activates JAK1 and TYK2, leading to the phosphorylation of STAT1 and STAT2 and the subsequent recruitment of interferon regulatory factor 9 (IRF9) to form the heterotrimeric transcription factor complex known as interferon-stimulated gene factor 3 (ISGF3) [87]. The ISGF3 complex translocates into the nucleus, where it binds to interferon-stimulated response elements (ISREs) in the promoter regions of hundreds of interferon-stimulated genes (ISGs), inducing an antiviral state [88].

Genetic variations that alter the kinetic properties of this signaling pathway can compromise host defense. Polymorphisms in the IFNAR1 and IFNLR1 genes have been associated with altered receptor density and downstream signaling efficiency. In individuals carrying alleles that reduce IFNAR1 expression, the induction of the antiviral state is delayed, allowing the virus to complete its replication cycle and package newly formed virions.

The different distribution of Type III interferon receptors, which are selectively expressed on epithelial cells, suggests that genetic variation in the Type III pathway has a highly localized, mucosal-specific impact on the persistence of infections within the cervical epithelium [89].

4.4.2. Interferon Regulatory Factors (IRF3, IRF5, and IRF7)

The transcriptional coordination of interferon production and the downstream response is regulated by a family of dedicated transcription factors known as interferon regulatory factors (IRFs). Among these, IRF3, IRF5, and IRF7 are critical for the defense against viral pathogens. IRF3 is constitutively expressed in an inactive cytoplasmic form and undergoes phosphorylation by TBK1 or I-kappa-B kinase-epsilon (IKKepsilon) upon pattern recognition receptor activation, leading to homodimerization and nuclear translocation [90].

Genetic polymorphisms in the IRF3 coding sequence, such as the single-nucleotide variant rs11264359, can alter the phosphorylation efficiency or the stability of the dimer complex, reducing the output of interferon-beta transcription.

Similarly, IRF7 is considered the master regulator of the Type I interferon response because it drives the positive feedback loop that amplifies the expression of multiple IFN-α subtypes. Single-nucleotide polymorphisms within the promoter region of IRF7 can reduce its basal expression levels, preventing the activation of this amplification loop during the early stages of viral exposure [91].

Genetic variations in IRF5 have been shown to affect the polarization of local macrophages, shifting them toward a less protective regulatory phenotype. The presence of these polymorphic variations in key regulatory nodes of the interferon pathway reduces the cumulative host response, enabling high-risk human papillomavirus genotypes to establish persistent infections while evading early immune elimination [92].

4.4.3. Interferon-Stimulated Gene (ISG) Activation and Viral Evasion

The execution of the antiviral state is carried out by the collective action of interferon-stimulated genes, which target multiple stages of the viral life cycle. Key antiviral effectors include 2'-5'-oligoadenylate synthetase 1 (OAS1), myxovirus resistance protein 1 (MX1), and interferon-stimulated gene 15 (ISG15). OAS1 is activated by viral double-stranded RNA and synthesizes oligoadenylates that activate ribonuclease L (RNaseL), leading to the degradation of viral RNA [93].

Single-nucleotide polymorphisms in the OAS1 gene, such as the splice-site variant rs11314454, can alter the enzymatic activity of the protein, compromising the host's capacity to degrade viral transcripts.

The protective actions of these genes are countered by high-risk human papillomavirus oncoproteins, which have evolved specific mechanisms to block their activity. The E6 oncoprotein binds directly to IRF3, preventing its nuclear translocation, while the E7 oncoprotein physically associates with IRF9, disrupting the assembly of the ISGF3 complex and blocking the transcription of downstream interferon-stimulated genes [94].

In a host with a genetic profile characterized by low-producing alleles of these genes, this viral inhibition is highly effective. The combination of inherited host genetic susceptibility and viral-mediated inhibition suppresses the cell-intrinsic immune response, allowing the virus to replicate without host interference. This biological synergy is a key factor driving long-term viral persistence and progression to cervical carcinogenesis [95].

5. Non-Immune Genetic Pathways

5.1. DNA Repair Mechanisms and Genomic Integrity

5.1.1. Base Excision Repair (BER) Pathways and XRCC1

While immune-mediated clearance is the primary defense against persistent infection, the preservation of genomic integrity within infected epithelial cells is critical for preventing progression to malignancy. The physical stress of chronic viral replication, combined with the continuous production of reactive oxygen species during inflammation, induces significant DNA damage in the host cell genome. The Base Excision Repair (BER) pathway is the primary mechanism responsible for repairing small base lesions, single-strand breaks, and oxidative damage [96].

A central scaffold protein in this pathway is X-ray repair cross-complementing group 1 (XRCC1), which coordinates the recruitment of DNA polymerase beta, DNA ligase III, and poly(ADP-ribose) polymerase 1 (PARP1) to the site of repair.

The XRCC1 gene contains several functional single-nucleotide polymorphisms, most notably the Arg399Gln (rs25487) substitution in the BRCT1 domain, which is involved in binding to PARP1. The Gln/Gln genotype is associated with a diminished capacity to repair single-strand breaks, leading to an accumulation of unrepaired lesions [97].

During DNA replication, these unresolved single-strand breaks can collapse into double-strand breaks, which are highly recombinogenic. In cells persistently infected with human papillomavirus, these double-strand breaks provide primary insertion sites for the integration of the viral episome into the host genome. This integration is an important step in neoplastic transformation.

5.1.2. Nucleotide Excision Repair (NER) Complexes and ERCC1

The repair of bulkier DNA adducts, such as those induced by environmental carcinogens or cross-linking agents, is mediated by the Nucleotide Excision Repair (NER) pathway. This multi-subunit complex consists of damage recognition factors, endonucleases, and helicases that excise a 24-to-32-nucleotide fragment containing the lesion. Excision repair cross-complementing 1 (ERCC1), which forms a heterodimer with the XPF endonuclease, is responsible for executing the 5' incision relative to the DNA lesion [98].

Polymorphic variations in the ERCC1 gene, such as the synonymous codon variant Asn118Asn (rs11615), can reduce translation efficiency and decrease cellular levels of the active endonuclease.

This reduction in ERCC1 expression impairs the efficiency of nucleotide excision repair, leading to the persistence of bulky DNA lesions and genomic instability. When these mutations accumulate in key tumor suppressor genes or proto-oncogenes, they accelerate neoplastic progression in cells expressing the viral oncoproteins E6 and E7 [99].

The physical interaction between ERCC1 and the transcription-coupled repair machinery is critical for resolving transcription-blocking lesions. This mechanism is often stressed by the high transcription rates of viral genes in integrated lesions, showing how genetic variations in the nucleotide excision repair pathway can cooperate with viral oncoproteins to drive genomic instability.

5.1.3. Double-Strand Break Repair and Homologous Recombination Genes

Double-strand DNA breaks are the most lethal forms of genetic damage, requiring repair by either the error-free Homologous Recombination (HR) pathway or the error-prone Non-Homologous End Joining (NHEJ) pathway. Homologous recombination relies on the activity of critical tumor suppressors, including breast cancer 1 (BRCA1), breast cancer 2 (BRCA2), ataxia telangiectasia mutated (ATM), and the recombinase RAD51 [100].

Inherited variations in these genes can compromise repair, promoting genomic instability. Single-nucleotide polymorphisms in the ATM gene can reduce its kinase activity, preventing the phosphorylation of downstream checkpoint kinases (CHK1 and CHK2) in response to double-strand breaks.

This signaling failure prevents the activation of the intra-S-phase checkpoint, allowing the replication of damaged DNA to continue. In cells expressing the E7 oncoprotein, which overrides the G1/S checkpoint, this genomic instability is amplified, causing rapid accumulation of structural chromosomal abnormalities [101].

Polymorphisms in the RAD51 gene can alter the stability of the nucleoprotein filament required for strand invasion during homologous recombination. The failure of this error-free repair pathway forces the cell to rely on non-homologous end joining, which frequently introduces deletions, insertions, and translocations. This genomic instability accelerates cellular transformation and the transition from pre-invasive lesions to invasive cervical carcinoma, highlighting the role of double-strand break repair genes as major modulators of host susceptibility.

5.2. Cell Cycle Regulation and Somatic Tumor Suppressors

5.2.1. TP53 Polymorphisms and Susceptibility to Degradation

The TP53 gene, located on chromosome 17p13.1, encodes the p53 tumor suppressor protein, which serves as a master regulator of cell cycle arrest, senescence, and apoptosis in response to cellular stress. In the context of human papillomavirus-mediated carcinogenesis, p53 is targeted for degradation by the viral oncoprotein E6 via the ubiquitin-proteasome pathway.

A common single-nucleotide polymorphism in codon 72 of the TP53 gene, resulting in a proline-to-arginine substitution (Pro72Arg, rs1042522), has been evaluated for its potential role in modifying susceptibility to cervical neoplasia [102].

Biochemical investigations have showed that the Arg72 isoform of p53 exhibits a higher binding affinity for the E6 oncoprotein than the Pro72 isoform, which correlates with faster degradation kinetics [103].

Epidemiological association studies have yielded conflicting results across different ancestral populations, likely due to variations in the baseline frequency of the Arg72 allele and differences in the distribution of high-risk viral genotypes. However, in cohorts carrying the susceptible Arg72/Arg72 genotype, the rapid depletion of p53 eliminates the host's capacity to induce cell cycle arrest at the G1/S transition or promote apoptosis of cells with genomic damage. This allows the clonal expansion of cells harboring integrated viral genomes and structural mutations, facilitating malignant progression.

5.2.2. CDKN2A Locus Variations and p16INK4a Expression

The CDKN2A locus on chromosome 9p21.3 encodes two distinct tumor suppressor proteins via alternative reading frames: $p16^{INK4a}$, a cyclin-dependent kinase inhibitor, and $p14^{ARF}$, an activator of p53. $p16^{INK4a}$ is a critical regulator of the retinoblastoma pathway, inhibiting the cyclin-dependent kinases CDK4 and CDK6 to maintain pRb in its active, hypophosphorylated state [104].

In high-grade cervical lesions, the inactivation of pRb by the viral E7 oncoprotein relieves the feedback inhibition of $p16^{INK4a}$ transcription, leading to its marked overexpression. This overexpression serves as a diagnostic surrogate biomarker for oncogenic transition.

Genetic variations within the CDKN2A gene, including single-nucleotide polymorphisms in the promoter or regulatory elements, can alter the baseline transcription rate and stability of $p16^{INK4a}$ and $p14^{ARF}$ transcripts. Polymorphisms that reduce the expression of $p16^{INK4a}$ can impair the host cell's baseline tumor suppressor response, facilitating cell cycle progression even in the absence of high E7 oncoprotein expression [105].

Additionally, genetic variations that compromise the functional activity of $p14^{ARF}$ reduce its capacity to inhibit MDM2-mediated degradation of p53, magnifying the oncogenic effect of the E6 oncoprotein. These findings indicate that genetic variations in the CDKN2A locus can cooperate with viral oncoproteins to accelerate cell cycle deregulation and neoplastic transformation.

5.2.3. Cyclin-Dependent Kinases and Retinoblastoma Pathway Regulators

The control of eukaryotic cell division is regulated by the sequential activation and inactivation of cyclin-dependent kinases (CDKs) and their regulatory cyclin partners. The transition from G1 to S phase is driven by the cyclin D-CDK4/6 and cyclin E-CDK2 complexes, which phosphorylate the retinoblastoma protein (pRb) to release the transcription factor E2F [106].

Inherited variations in genes encoding these cell cycle regulators can alter their baseline enzymatic activity or sensitivity to negative regulatory signals, modifying overall cancer risk.



Figure 4. Non-immune pathways and host cell genomic checkpoint vulnerabilities.

Left: Base Excision Repair (BER) pathway kinetics under chronic oxidative stress. In wild-type hosts, the XRCC1 scaffold recruits DNA polymerase beta and DNA ligase III to repair single-strand breaks. In individuals carrying the functional polymorphic Arg399Gln variant, delayed assembly allows single-strand breaks to collapse into double-strand breaks during replication, facilitating viral genomic integration. Right: The impact of the TP53 codon 72 polymorphism (Pro72Arg) on susceptibility to E6-mediated proteasomal degradation. The Arginine-72 isoform exhibits a higher binding affinity for the E6-E6AP complex than the Proline-72 isoform, leading to rapid degradation and the elimination of DNA damage checkpoints

Polymorphisms in the CCND1 gene, which encodes cyclin D1, can result in the production of alternative splice variants (such as cyclin D1b) with increased nuclear stability, promoting prolonged activation of CDK4. This prolonged activation enhances the phosphorylation of pRb, cooperating with the viral E7 oncoprotein to drive uncontrolled cell division [107].

Additionally, genetic variations in the cyclin-dependent kinase inhibitors CDKN1A ($p21^{CIP1}$) and CDKN1B ($p27^{KIP1}$) have been shown to alter their inhibitory capacity. Polymorphisms that impair $p21^{CIP1}$ binding to CDK2 complexes prevent cell cycle arrest in response to DNA damage, reinforcing the loss of genomic safeguards caused by E6-mediated p53 degradation. This multi-layered deregulation of the cell cycle highlights the cooperative interactions between host genetic variations and viral oncoproteins in driving carcinogenesis.

Table 3. Non-Immune Pathways: DNA Repair, Cell Cycle, and Epigenetic Loci in Neoplastic Pathogenesis

Pathway / Machinery	Gene Locus	SNP ID / Amino Acid Change	Cellular/Genomic Consequence	Impact on Oncogenic Transition Stages	References
Base Excision Repair (BER)	XRCC1	rs25487 (Arg399Gln)	Diminishes scaffold binding affinity for PARP1 within the BRCT1 domain, delaying single-strand break repair.	Accumulates recombinogenic double-strand breaks, directly facilitating the integration of the viral episome into the host genome.	[96], [97]
Nucleotide Excision Repair (NER)	ERCC1	rs11615 (Asn118Asn)	Reduces translation efficiency, decreasing cellular levels of the active ERCC1-XPF endonuclease complex.	Restricts the excision of bulky DNA adducts and transcription-blocking lesions, accelerating the somatic mutation rate.	[98], [99]
Double-Strand Break Repair (HR)	ATM	Kinase-domain polymorphisms	Attenuates the phosphorylation kinetics of upstream checkpoint kinases (CHK1/CHK2) under genomic stress.	Prevents activation of the intra-S-phase checkpoint, allowing damaged host DNA to replicate alongside viral oncoproteins.	[100], [101]
Cell Cycle Checkpoint	TP53	rs1042522 (Pro72Arg)	The Arg72 isoform displays significantly higher binding and ubiquitination affinity for the E6-E6AP complex.	Accelerates the proteasomal degradation of p53, abolishing the host cell's baseline DNA-damage-induced apoptotic pathways.	[102], [103]
Retinoblastoma Pathway	CDKN2A	Promoter and alternate reading frame variants	Alters transcriptional stability of the $p16^{INK4a}$ and $p14^{ARF}$ tumor suppressor transcripts.	Impairs MDM2 inhibition and compromises baseline cell cycle arrest, cooperating with E7-mediated pRb degradation.	[104], [105]
DNA Methylation	DNMT3B	rs1569688 (-149C>T)	Increases promoter transcriptional activity, elevating de novo methyltransferase cellular expression.	Promotes aberrant hypermethylation of host tumor suppressor promoter CpG islands, driving transcriptional silencing.	[108], [109]

5.3. Epigenetic Regulation and Host Chromatin Architecture

5.3.1. DNA Methyltransferase (DNMT) Polymorphisms

Epigenetic mechanisms, including DNA methylation and histone modifications, regulate gene expression without altering the underlying genomic sequence. The establishment and maintenance of DNA methylation patterns are mediated by DNA methyltransferases (DNMTs), with DNMT1 serving as the primary maintenance methyltransferase, and DNMT3A and DNMT3B acting as de novo methyltransferases [108].

Polymorphic variations in genes encoding these methyltransferases can alter their enzymatic activity, leading to aberrant global or gene-specific methylation profiles.

For instance, the promoter polymorphism -149C>T (rs1569688) in the DNMT3B gene is associated with increased transcriptional activity and elevated methyltransferase levels. This elevated expression can promote hypermethylation of promoter CpG islands in host tumor suppressor genes, such as CDKN2A and CDH1, leading to their transcriptional silencing [109].

In cells infected with high-risk human papillomavirus, this epigenetic silencing of host tumor suppressors cooperates with viral oncoprotein activity to accelerate cellular transformation. Concurrently, viral oncoproteins can physically associate with and stimulate the activity of DNMTs, showing how host genetic variation and viral activity interact to drive epigenetic deregulation.

5.3.2. Histone Methyltransferases and Acetyltransferases

The accessibility of genomic DNA to transcription factor complexes is regulated by post-translational modifications of histone tails, which are catalyzed by histone methyltransferases, demethylases, acetyltransferases, and deacetylases. Histone acetylation, mediated by histone acetyltransferases (HATs), neutralizes the positive charge of lysine residues, promoting an open chromatin structure that favors transcription.

Conversely, histone deacetylases (HDACs) remove acetyl groups, leading to chromatin compaction and transcriptional silencing [110].

Genetic polymorphisms in genes encoding these chromatin-modifying enzymes can alter the transcriptional landscape of both the host cell and the integrated viral genome. Single-nucleotide polymorphisms that increase the activity or expression of HDAC1 can enhance the silencing of host genes involved in antigen presentation and antiviral defense.

At the same time, variations in histone methyltransferases, such as EZH2 (a component of the Polycomb Repressive Complex 2), can lead to elevated trimethylation of histone H3 lysine 27 (H3K27me3), silencing tumor suppressor genes and promoting cell survival [111]. This epigenetic deregulation can also affect the viral genome; integration-associated modifications in histone methylation on the viral long control region can enhance the transcription of the E6 and E7 oncogenes, accelerating the oncogenic transition.

5.3.3. Non-Coding RNA Networks and Post-Transcriptional Silencing

The post-transcriptional regulation of cellular gene expression is controlled by networks of non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). These molecules bind to target messenger RNAs (mRNAs) to induce their degradation or inhibit translation.

Inherited variations within miRNA genes, their promoter regions, or their target mRNA binding sites known as microRNA-related single-nucleotide polymorphisms (miRSNPs) can disrupt these regulatory networks, modifying cancer susceptibility [112].

A well-characterized example is the rs2910164 polymorphism in the precursor sequence of miR-146a. The C allele reduces the processing efficiency of the primary microRNA transcript, leading to lower levels of mature, active miR-146a. Since miR-146a is a key negative regulator of innate immune signaling that targets TRAF6 and IRAK1, its down-regulation can lead to dysregulated inflammation.

Similarly, polymorphisms in the binding sites of miRNAs within the 3' untranslated regions of tumor suppressor genes can prevent efficient binding, causing uncontrolled expression of target oncogenes or silencing of protective factors. In cells persistently infected with human papillomavirus, these microRNA alterations can cooperate with viral oncoproteins to disrupt cell cycle control and immune signaling, highlighting the complex role of non-coding RNAs in susceptibility to carcinogenesis.

6. Genome-Wide Association Studies (GWAS) and Genomic Dissection

6.1. Highly Replicated Genomewide Loci

6.1.1. MHC Region Findings and Extramajor Histocompatibility Loci

Genome-wide association studies have advanced our understanding of genetic susceptibility to human papillomavirus persistence and cervical carcinogenesis by evaluating millions of single-nucleotide polymorphisms across the entire genome without prior functional assumptions. The most robust and consistently replicated signals identified in these large-scale genomic analyses are located within the major histocompatibility complex (MHC) region on chromosome 6p21.3.

The strongest association signals consistently peak near the HLA-DRB1 and HLA-DQA1 genes, reinforcing the critical role of HLA class II-mediated antigen presentation in determining the clinical course of viral exposure.

However, recent genome-wide association studies have also identified several novel susceptibility loci located outside the major histocompatibility complex region. Among these, the gasdermin B (GSDMB) gene locus on chromosome 17q21.1 has emerged as a key replicated signal. GSDMB is a member of the gasdermin family, which regulates pyroptosis a highly inflammatory form of programmed cell death.

Polymorphisms associated with altered GSDMB expression can compromise the induction of pyroptosis in infected epithelial cells, preventing the release of intracellular pro-inflammatory signals and allowing the virus to replicate without host interference.

Another important extramajor histocompatibility locus is the mucin 1 (MUC1) gene on chromosome 1q22, which encodes a transmembrane glycoprotein that forms an essential component of the mucosal physical barrier in the female reproductive tract. Polymorphisms that alter the glycosylation pattern or expression levels of MUC1 can compromise mucosal barrier integrity, facilitating viral entry and access to the basal epithelial cells.

6.1.2. Loci Regulating Epithelial Structure and Adhesion

In addition to immune-related loci, genome-wide association studies have identified key susceptibility genes involved in regulating the structural integrity and cell-cell adhesion of stratified squamous epithelia. The entry of human papillomavirus into basal keratinocytes is facilitated by microabrasions that expose the basement membrane.

Genomic variants that alter the expression or structural stability of epithelial cell adhesion molecules can increase susceptibility to viral entry and initial infection.

Among these, polymorphisms in the desmoglein 2 (DSG2) and cadherin 1 (CDH1, encoding E-cadherin) genes have shown significant association with increased risk of cervical neoplasia. Desmoglein 2 is a key component of desmosomes, which coordinate intercellular adhesion and provide mechanical resistance to epithelial tissues.

Polymorphisms that reduce DSG2 expression can compromise desmosomal assembly, making the cervical epithelium more susceptible to physical shear stress and microabrasions, which facilitates viral access to basal cells.

Similarly, E-cadherin is essential for maintaining cell-cell junctions and regulating epithelial barrier function. The downregulation of E-cadherin is a hallmark of epithelial-to-mesenchymal transition, a process that is accelerated by the viral oncoproteins E6 and E7. Inherited polymorphisms that reduce baseline E-cadherin expression can cooperate with these viral proteins to accelerate tissue remodeling, promoting the transition from pre-invasive lesions to invasive cervical carcinoma.

6.1.3. Transcriptional Coactivators and Differentiation Pathways

The life cycle of the human papillomavirus is dependent on the differentiation program of host stratified squamous epithelial cells. Consequently, host transcription factors and coactivators that regulate epithelial differentiation are critical determinants of viral replication efficiency and susceptibility to persistent infection.

Genome-wide association studies have identified several key susceptibility loci within genes regulating these pathways. Among these, polymorphisms in the transcription factor AP-2 alpha (TFAP2A) gene on chromosome 6p24.3 have shown strong association with cervical cancer risk. TFAP2A is a master regulator of ectodermal differentiation, controlling the transcription of multiple genes involved in epithelial cell growth, adhesion, and differentiation.

Polymorphisms that reduce the binding affinity of TFAP2A or alter its downstream transcriptional activity can disrupt the normal differentiation program of host epithelial cells. In cells infected with human papillomavirus, this disruption can lead to an accumulation of undifferentiated, proliferating cells in the intermediate and superficial layers of the epithelium, providing an environment that supports viral replication and oncogene expression.

Additionally, genetic variations in the mastermind-like transcriptional coactivator 2 (MAML2) gene, a key component of the Notch signaling pathway, have been implicated in susceptibility. The Notch signaling pathway is essential for regulating epithelial differentiation and maintaining tissue homeostasis. Polymorphisms that alter MAML2 function can disrupt this pathway, cooperating with viral oncoproteins to promote uncontrolled cell proliferation and malignant transformation.

6.2. Polygenic Risk Score (PRS) Modeling and Clinical Stratification

6.2.1. Mathematical Construction and Weighting of Loci

The polygenic nature of susceptibility to human papillomavirus persistence and cervical carcinogenesis means that single-nucleotide polymorphisms typically exhibit small individual effect sizes, with odds ratios (ORs) ranging from 1.05 to 1.25. To capture the cumulative effect of these multiple genetic variants, researchers use Polygenic Risk Scores (PRSs).

The mathematical construction of a polygenic risk score integrates information across multiple risk loci identified in large-scale genome-wide association studies, weighting each risk allele by its estimated effect size (log-odds ratio) derived from the discovery cohort.

Mathematically, the polygenic risk score (PRS) for an individual j is calculated using the following linear combination:

$$PRS_j = \sum_{i=1}^{M} \beta_i G_{ij}$$

where M represents the total number of single-nucleotide polymorphisms included in the predictive model, βi represents the estimated log-odds ratio for the risk allele of polymorphism i, and Gij represents the dosage of the risk allele for individual j at polymorphism i (which can take values of 0, 1, or 2, corresponding to homozygous wild-type, heterozygous, or homozygous mutant genotypes, respectively).

The selection of polymorphisms to include in the model can be performed using threshold-based methods (such as including only variants that meet the genome-wide significance threshold of $P < 5$ times 10^{-8} or bayesian modeling approaches (such as LDpred), which incorporate linkage disequilibrium patterns to adjust the effect size weights of correlated variants. This mathematical modeling allows for the quantification of an individual's baseline genetic liability.

6.2.2. Multi-Locus Risk Prediction Models in Clinical Screening

The integration of polygenic risk scores into clinical screening algorithms represents an opportunity to improve risk stratification and develop personalized screening strategies. Under current clinical guidelines, cervical cancer screening is based on age-dependent cytological evaluation and high-risk human papillomavirus DNA testing, which are performed at fixed intervals for all women in the screening population.

Clinicians could customize screening intervals and diagnostic interventions based on their baseline genetic liability by incorporating an individual's polygenic risk score.

For example, women in the highest decile of the polygenic risk score distribution exhibit a significantly increased risk of viral persistence and rapid progression to high-grade intraepithelial lesions (CIN2/3). These high-risk individuals could benefit from more frequent screening, early initiation of high-risk HPV DNA testing, and a lower threshold for colposcopic referral upon detection of low-grade cytological abnormalities.

Conversely, women in the lowest decile of the polygenic risk score distribution, who possess a highly protective genetic profile, could be safely managed with extended screening intervals. This personalized approach could reduce the clinical burden and costs associated with over-screening and unnecessary diagnostic interventions. This clinical integration could optimize resource allocation and improve the cost-effectiveness of screening programs, particularly in resource-constrained settings.

6.2.3. Cross-Ancestral Predictive Performance and Calibration Challenges

A major limitation in the clinical translation of polygenic risk scores is their poor generalizability across ancestrally diverse populations. The vast majority of large-scale genome-wide association studies of human papillomavirus persistence and cervical cancer have been conducted in cohorts of European and East Asian ancestry.

Because patterns of linkage disequilibrium, risk allele frequencies, and background environmental exposures vary substantially across different geographic ancestries, a polygenic risk score calibrated in European populations often exhibits a significant loss of predictive accuracy when applied to non-European cohorts, such as populations of sub-Saharan African or Latin American descent.

This loss of predictive performance is particularly concerning given that the burden of cervical cancer is highest in low- and middle-income countries, where populations are ancestrally diverse and underrepresented in genomic databases. If polygenic risk scores are

integrated into clinical screening guidelines without rigorous cross-ancestral validation and recalibration, they risk exacerbating existing health disparities.

To address this challenge, researchers must expand genomic discovery efforts to encompass diverse populations, utilizing multi-ethnic genome-wide association studies and advanced statistical methods to identify causal variants that are shared across ancestries. This ancestral recalibration is essential to ensure that the benefits of precision medicine are shared equitably across global populations.

6.3. Biological and Methodological Bottlenecks of Genomic Research

6.3.1. Statistical Power and Low-Frequency Variant Identification

Despite the success of genome-wide association studies in identifying common susceptibility variants, a significant proportion of the heritable liability to human papillomavirus persistence remains unexplained a phenomenon known as missing heritability. A major contributing factor is the lack of statistical power to detect low-frequency (MAF = 0.001 - 0.01) and rare (MAF < 0.001) genetic variants, which may possess larger individual effect sizes than common single-nucleotide polymorphisms.

To identify these low-frequency variants, genomic research requires massive sample sizes, which are difficult to assemble for specific clinical phenotypes like longitudinal viral persistence.

The statistical power of genome-wide association studies is compromised by the strict significance thresholds required to correct for multiple testing, which can lead to the rejection of true susceptibility loci with modest effect sizes. To overcome this limitation, researchers are transitioning to next-generation sequencing approaches, including whole-exome sequencing and whole-genome sequencing, which allow for the direct identification of rare coding and regulatory variants.

However, the high cost of sequencing and the need for complex bioinformatics pipelines remain barriers to their widespread application in large-scale epidemiological studies. This highlight the need for continued investment in large, well-characterized clinical cohorts to provide the statistical power necessary to map the rare genetic variants that contribute to host susceptibility.

6.3.2. Epigenomic Partitioning and Causal Variant Mapping in Non-Coding Regions

A major biological challenge in interpreting genome-wide association studies is that the vast majority of identified susceptibility variants lie within non-coding regions of the genome, such as introns, intergenic regions, and gene regulatory elements. These variants do not alter the amino acid sequence of proteins; instead, they modulate gene expression by disrupting transcription factor binding sites, enhancers, or splicing regulatory elements.

To identify the causal variants among hundreds of highly correlated single-nucleotide polymorphisms in linkage disequilibrium, researchers use epigenomic partitioning and functional genomic annotations.

This functional mapping involves integrating genome-wide association study data with tissue-specific epigenomic databases, such as the Roadmap Epigenomics Project and ENCODE. Researchers can identify variants that lie within active enhancer elements or promoter regions in primary cervical keratinocytes and immune cells by overlaying susceptibility loci with chromatin accessibility maps (DNase-seq, ATAC-seq) like histone modification signatures (H3K4me1, H3K27ac), and expression quantitative trait loci (eQTL) data.

This functional prioritization allows for the identification of candidate target genes that are regulated by these non-coding variants. However, translating these statistical associations into validated biological mechanisms requires labor-intensive functional studies, including reporter assays, CRISPR-mediated gene editing, and cellular models of viral infection, which remain major bottlenecks in genomic research.

6.3.3. Phenotypic Heterogeneity and Misclassification Bias

The validity and generalizability of genetic epidemiological findings depend on the precision and consistency of the clinical phenotypes used in genetic association studies. A major methodological bottleneck in genomic research on human papillomavirus is the lack of standardized definitions for the key clinical outcomes: infection, clearance, and persistence.

Many early studies relied on cross-sectional clinical data, which can lead to significant phenotyping errors and misclassification bias.

For instance, a single positive test for high-risk human papillomavirus DNA cannot distinguish between a transient, self-limiting infection and a true, long-term persistent state. If individuals with transient infections are misclassified as persistent cases, the statistical power of the genetic association analysis is compromised, which can lead to a failure to identify true susceptibility loci.

To address this challenge, genomic research must utilize longitudinal cohort designs with standardized clinical phenotyping, defining persistence based on the detection of the identical high-risk human papillomavirus genotype at multiple consecutive study visits over a minimum period of 12 or 24 months.

Additionally, the clinical staging of cervical intraepithelial neoplasia can exhibit significant inter-observer variability, which can introduce misclassification bias. Standardizing clinical protocols, using digital pathology, and incorporating molecular markers can help minimize phenotyping errors, ensuring the robustness and reproducibility of genetic epidemiological findings.

7. Gene–Environment and Gene–Viral Interactions

7.1. Environmental and Behavioral Cofactors in Genetic Susceptibility

7.1.1. Tobacco Smoke Mutagens and Host DNA Repair Capacity

The progression of a persistent high-risk human papillomavirus infection to clinical malignancy is heavily influenced by exposure to environmental carcinogens, which interact with host genetic variants to accelerate genomic instability. Among these environmental factors, tobacco smoking is established as a major behavioral cofactor that elevates the risk of cervical carcinogenesis [113]. Tobacco smoke contains a complex mixture of polycyclic aromatic hydrocarbons, nitrosamines, and volatile organic compounds that are absorbed systemically and delivered to the cervical mucosa via the pelvic vasculature. Once inside host epithelial cells, these lipophilic pro-carcinogens undergo metabolic activation by Phase I cytochrome P450 enzymes, such as CYP1A1 and CYP1B1, converting them into highly reactive electrophilic intermediates like benzo[a]pyrene diol epoxide [114]. These reactive metabolites bind covalently to genomic DNA, forming bulky DNA adducts that block DNA replication and transcription.

Under physiological conditions, these bulky lesions are recognized and excised by the nucleotide excision repair pathway, while oxidative DNA lesions are processed by the base excision repair pathway. However, in individuals carrying inherited polymorphic variants that compromise these repair pathways, the accumulation of tobacco-induced DNA damage is significantly accelerated [115]. For example, when the susceptible XRCC1 Arg399Gln (rs25487) genotype is co-inherited with high-producing polymorphic variants of the Phase I metabolizing enzyme CYP1A1, the intracellular concentration of electrophilic DNA-damaging intermediates rises while the rate of base excision repair falls.

This gene-environment interaction leads to a rapid accumulation of double-strand DNA breaks, which are highly recombinogenic and facilitate the integration of episomal viral DNA into the host genome [116]. This genomic integration is a key step in neoplastic transformation, showing how environmental mutagens and inherited DNA repair deficiencies cooperate to drive carcinogenesis.

7.1.2. Exogenous Steroid Hormones and Epigenetic Synergy

The long-term administration of exogenous steroid hormones, particularly via oral contraceptives, is associated with an increased risk of persistent human papillomavirus infection and subsequent progression to cervical neoplasia [117]. The cervical epithelium and underlying stromal cells express high levels of nuclear estrogen receptors (ERα and ERbeta) and progesterone receptors (PR). These receptors function as ligand-activated transcription factors that regulate cell proliferation, differentiation, and tissue remodeling within the cervical transformation zone. Exogenous estrogen and progesterone stimulate the transcription of the viral oncogenes E6 and E7 by binding directly to hormone response elements located within the viral long control region [118]. This hormonal activation of viral transcription is enhanced in individuals with specific host genetic variants in steroid hormone receptor genes and metabolic pathways.

Polymorphisms within the estrogen receptor 1 (ESR1) gene, such as the classical PvuII (rs2234693) and XbaI (rs9340799) restriction fragment length polymorphisms, alter the transcriptional activity of the receptor complex. In individuals carrying high-activity receptor variants, the binding of exogenous synthetic estrogens induces a sustained upregulation of E6 and E7 oncoproteins, accelerating the degradation of p53 and pRb [119].

This hormonal stimulation interact with host epigenetic machinery. Progesterone signaling upregulates the expression of host DNA methyltransferases, particularly DNMT1 and DNMT3B. In individuals carrying high-producing promoter polymorphisms in these methyltransferase genes, this hormonal signaling promotes hypermethylation of host tumor suppressor genes, leading to transcriptional silencing [120]. This epigenetic synergy shows how exogenous steroid hormones can interact with inherited host genetic variations to drive epigenetic deregulation and malignant transformation.

7.1.3. Vaginal Dysbiosis and Mucosal Barrier Dynamics

The mucosal surface of the female reproductive tract represents the first line of defense against viral invasion, and its physical and immunological barrier properties are regulated by interactions with the resident vaginal microbiota. Under physiological conditions, a healthy vaginal microbiome is dominated by *Lactobacillus* species, particularly *Lactobacillus crispatus*, which metabolize glycogen to produce high concentrations of lactic acid [121]. This biochemical activity maintains an acidic vaginal microenvironment (pH < 4.5) and generates hydrogen peroxide and bacteriocins, which inhibit the colonization of pathogenic bacteria and maintain mucosal barrier integrity.

Table 4. Role of Host Immunogenetics, Vaginal Microbiome, and Mucosal Barrier Proteins

Host Genetic Locus	Mucosal Barrier Protein	Interacting Microbiome State	Molecular Pathological Cascade	Impact on Viral Lifecycle / Carcinogenesis	References
MUC1	Transmembrane Mucin 1	Anaerobic Vaginal Dysbiosis (*Gardnerella vaginalis*, *Atopobium vaginae*)	Microbial secretion of sialidases and mucinases degrades the low-complexity mucin fibers produced by polymorphic MUC1 variants, compromising the physical barrier.	Promotes high-risk viral particle access to the basal epithelial layers, facilitating initial attachment and receptor-mediated endocytosis.	[121], [123]
DSG2	Desmoglein 2	Depleted *Lactobacillus* species (*L. crispatus*)	Loss of microbial lactic acid production elevates mucosal pH; combined with inherited desmosomal assembly deficits in DSG2, this increases susceptibility to microabrasions.	Creates physical micro-lesions in the cervical epithelium, exposing basement membrane heparan sulfate proteoglycans for viral binding.	[122], [123]
HLA-DRB1	HLA Class II Heterodimer	Chronic inflammatory dysbiosis (*Prevotella*, *Mobiluncus*)	Chronic bacterial stimulation induces local MHC class II expression on non-professional antigen-presenting cells, but susceptible alleles (DR15) fail to present viral L1/E7 epitopes effectively.	Establishes a chronic, non-protective inflammatory state that promotes mucosal cell proliferation while allowing the virus to escape adaptive clearance.	[58], [63], [67]
CDH1	E-cadherin	High bacterial diversity / Elevated local cytokines (IL-6, TNF-α)	Pro-inflammatory cytokines downregulate E-cadherin expression; inherited CDH1 variants amplify this loss, accelerating the disassembly of adherens junctions.	Cooperates with the viral E7 oncoprotein to trigger epithelial-to-mesenchymal transition, facilitating invasive cellular migration.	[109], [122]

Conversely, a shift toward vaginal dysbiosis characterized by a loss of *Lactobacillus* species and an overgrowth of anaerobic bacteria such as *Gardnerella vaginalis*, *Atopobium vaginae*, and *Prevotella* species disrupts this protective barrier, elevating the risk of human papillomavirus acquisition and persistence [122].

The biochemical mechanisms underlying this dysbiosis-mediated susceptibility involve the production of microbial enzymes, such as sialidases and prolidases, which degrade the protective mucin layer covering the cervical epithelium. The impact of this microbial enzymatic activity is modified by host genetic variants that regulate epithelial structural integrity.

Polymorphic variations in genes encoding mucins, such as the transmembrane mucin 1 (MUC1) gene, can reduce the baseline complexity of the mucosal physical barrier. In individuals carrying these compromised mucin variants, microbial enzymatic degradation can expose the underlying cell adhesion molecules [123].

Inherited polymorphisms in the desmoglein 2 (DSG2) gene, which compromise desmosomal cell-cell adhesion, increase the susceptibility of the epithelium to physical shear stress and microabrasions during sexual intercourse. This loss of mucosal barrier integrity facilitates viral access to the basal keratinocytes, showing how vaginal dysbiosis and host genetic variations in structural proteins cooperate to promote viral entry and persistent infection.

7.2. Viral Genetic Variation and Intratypic Heterogeneity

7.2.1. Intratypic Variants and Differential E6/E7 Oncogenic Potency

The clinical outcome of a high-risk human papillomavirus infection is determined not only by the host genetic background but also by the genetic heterogeneity of the infecting viral population. While high-risk human papillomavirus genotypes are classified into distinct types based on sequence homology within the L1 gene, extensive intratypic genetic variation exists within each type. These intratypic variants, which differ in sequence by up to 10%, are classified into distinct phylogenetic lineages and sublineages [124].

For example, HPV 16 is categorized into four major lineages: European (A), Asian (B), African-1 (C), and African-2/Asian-American (D). These lineages exhibit significant variations in oncogenic potential, with non-European lineages, particularly the Asian-American (D) lineage, showing a higher risk of persistent infection and rapid progression to invasive cervical carcinoma.

The biochemical basis of this differential oncogenicity lies in specific amino acid substitutions within the viral oncoproteins E6 and E7, which alter their interaction kinetics with host cellular targets. In the Asian-American lineage of HPV 16, the E6 gene frequently harbors the D25E polymorphism, which results in an aspartic acid-to-glutamic acid substitution in the amino-terminal domain of the protein [125]. This structural modification increases the binding affinity of E6 for the host cellular ubiquitin ligase E6AP, accelerating the ubiquitination and subsequent proteasomal degradation of the host tumor suppressor p53.

Concurrently, these intratypic variants may exhibit altered interaction kinetics with host HLA class I and II molecules, modifying the efficiency of antigen presentation. If a host carrying a susceptible HLA class II genotype, such as HLA-DRB1*15:01, is infected with an HPV 16 variant harboring mutations in immunodominant T-cell epitopes, the immune system may fail to recognize and eliminate the infected cells. This joint host-virus genetic mismatch facilitates long-term viral persistence and accelerated carcinogenesis.

7.2.2. Genotypic Co-infections and Mucosal Immunological Competition

In natural populations, individuals are frequently exposed to multiple human papillomavirus genotypes simultaneously, leading to genotypic co-infections within the cervical epithelium. The epidemiological dynamics of these co-infections are highly complex and can influence the persistence of individual viral types. Within a co-infected tissue microenvironment, different viral genotypes may undergo immunological and metabolic competition for host cell resources and cellular entry receptors [126].

From an immunological perspective, the presence of one viral genotype may trigger a localized innate immune response that enhances mucosal surveillance, leading to the bystander clearance of co-infecting types. Conversely, specific viral combinations may synergize to suppress host defenses, facilitating mutual persistence.

The genetic basis of host susceptibility to these co-infections is linked to polymorphisms within innate pattern recognition and antigen presentation pathways. In individuals carrying alleles that reduce Toll-like receptor expression, such as the TLR9 -1486C variant, the local innate immune response is suppressed, allowing multiple viral genotypes to establish concurrent persistent infections [127].

Additionally, co-infection with multiple genotypes can stress the host's antigen presentation machinery. Professional antigen-presenting cells must process and present a highly diverse pool of viral peptides, and the limited availability of peptide-binding grooves on HLA molecules can lead to competitive displacement of immunogenic epitopes. If a host exhibits a restricted HLA class II repertoire, certain high-risk genotypes may escape immunological detection due to this competitive inhibition, promoting long-term persistence and neoplastic progression within the transformation zone.

7.3. Integrated Multilayered Risk Architecture

7.3.1. Pathway-Level Synergy and Cumulative Liability

The transition from an acute, transient human papillomavirus infection to invasive cervical carcinoma cannot be fully explained by any single genetic variant or environmental exposure. Instead, disease susceptibility is governed by a multilayered risk architecture, where pathway-level synergy between host genetics, viral genetic heterogeneity, and environmental cofactors determines cumulative liability.

This theory conceptualizes the carcinogenic process as a series of physiological barriers that the virus must breach to establish a malignancy. The host's first line of defense is the mucosal physical barrier, which is regulated by genes controlling epithelial structural integrity and cell adhesion, as well as the vaginal microbiota.

If the virus breaches this physical barrier, it encounters the host's innate immune surveillance system, which is regulated by Toll-like receptors, downstream signaling intermediates, and interferon regulatory factors [128]. If the virus evades early innate detection, it must then contend with the adaptive arm of the immune system, where HLA class I and II molecules determine the efficiency of cell-mediated elimination.



Figure 5. Comprehensive gene-environment-viral interaction cascades in high-risk mucosal exposure.

Baseline susceptibility is mediated by host mucosal barrier genes (e.g., MUC1 and DSG2 variants) in combination with resident vaginal microbiome ecosystems. If the epithelial physical barrier is compromised, basal keratinocyte infection takes place. Subsequent clearance kinetics are determined by immunogenetic patterns of presentation (HLA-DRB1) and recognition (TLR9). Hosts harboring low-efficiency variants across these functional checkpoints undergo persistent viral replication and rapid chromosomal integration, which are further accelerated by exogenous mutagens (such as tobacco smoke and oral steroid hormones) and genetic base excision repair deficiencies (XRCC1).

Finally, if the infection persists, the cellular stress of chronic replication puts a heavy demand on host DNA repair mechanisms and cell cycle checkpoints, which are regulated by genes such as XRCC1, ERCC1, TP53, and CDKN2A.

Pathway-level synergy occurs when a host carries susceptible alleles across multiple functional layers, creating a permissive microenvironment for viral replication, immune evasion, and cellular transformation. For instance, a host with inherited structural deficits in mucosal integrity, combined with compromised Toll-like receptor signaling and susceptible HLA class II alleles, will exhibit a highly elevated rate of viral persistence [129]. If this host is exposed to highly oncogenic non-European viral lineages and environmental mutagens like tobacco smoke, the cumulative genomic damage will quickly overwhelm cellular safeguards, driving rapid neoplastic progression. This integrated risk model highlights the polygenic nature of susceptibility to cervical carcinogenesis.

8. Pharmacogenomics of Prophylactic HPV Vaccination

8.1. Immunogenetic Determinants of Prophylactic Vaccine Efficacy

8.1.1. HLA Class II Allele-Specific Response to L1 Virus-Like Particles

Prophylactic human papillomavirus vaccines, such as the bivalent (Cervarix), quadrivalent (Gardasil), and nonavalent (Gardasil 9) formulations, are highly effective interventions designed to prevent infection with oncogenic viral genotypes. These vaccines utilize recombinant yeast or baculovirus expression systems to produce the major viral capsid protein L1, which spontaneously assembles into non-infectious, non-oncogenic virus-like particles (VLPs) [130]. The primary mechanism of action of these vaccines is the induction of a robust humoral immune response characterized by the production of high-titer, type-specific neutralizing antibodies that transudate across the cervical mucosa to neutralize incoming viral particles.

However, the magnitude of this protective antibody response exhibits substantial inter-individual variability, which is driven by host immunogenetic factors.

The generation of high-titer neutralizing antibodies against L1 virus-like particles is dependent on the activation of $CD4^+$ helper T-lymphocytes, which recognize viral peptides presented on HLA class II molecules. Dendritic cells and other professional antigen-presenting cells at the injection site internalize the vaccine antigen, process the L1 protein into peptide fragments, and present them within the peptide-binding grooves of HLA class II heterodimers.

Specific polymorphisms in the HLA-DRB1 and HLA-DQB1 genes determine the structural conformation of these binding grooves, directly affecting the affinity for immunodominant L1 epitopes [131].



Figure 6. Pharmacogenomic pathways of prophylactic vaccine immunogenicity and topical innate immunotherapy.
*Left: The immunogenetic basis of variability in neutralizing antibody titers following prophylactic L1 virus-like particle (VLP) vaccination. Dendritic cells process L1 proteins and present them on HLA class II molecules. High-affinity alleles, such as HLA-DRB1*04:01, induce robust helper T-cell priming, whereas alleles like HLA-DRB1*15:01 result in suboptimal presentation and weaker antibody responses. Right: The signaling cascade of topical Imiquimod, a TLR7/8 agonist, which recruits the MyD88-IRAK signalosome to bypass viral immune evasion and promote the targeted destruction of dysplastic cells.*

Structural and functional immunogenetic analyses have shown that individuals expressing the HLA-DRB1*04:01 and HLA-DRB1*07:01 alleles generate higher-affinity interactions with L1 peptides, leading to robust activation of follicular helper T-cells and extensive B-cell differentiation [132]. This translates clinically into highly elevated titers of neutralizing antibodies that persist for decades.

Conversely, individuals expressing the HLA-DRB1*15:01 or HLA-DRB1*03:01 alleles often exhibit a significantly lower quantitative antibody response. In these individuals, the structural configuration of the peptide-binding groove has a lower affinity for key L1 epitopes, resulting in weak $CD4^+$ helper T-cell priming and a diminished memory B-cell response. This immunogenetic variation explains a substantial portion of the inter-individual differences observed in vaccine-induced antibody titers.

8.1.2. Host Cytokine Gene Polymorphisms and Humoral Memory Durability

Beyond antigen presentation, the differentiation, proliferation, and survival of antibody-secreting plasma cells and memory B-cells are regulated by cytokine signaling networks. Single-nucleotide polymorphisms in genes encoding immunomodulatory cytokines or their receptors can influence the long-term durability of the vaccine-induced humoral immune response. Interleukin-4 (IL-4) and its receptor (IL-4R) are critical regulators of B-cell class switching to immunoglobulin G (IgG), the primary antibody isotype found in cervical secretions following vaccination [133].

Polymorphisms within the IL4 promoter, such as the -590C>T (rs2243250) transition, increase transcription levels of the cytokine, promoting follicular helper T-cell-induced B-cell activation and enhancing neutralizing antibody production.

Concurrently, interleukin-10 (IL-10), encoded by the IL10 gene, is essential for the differentiation of activated B-cells into antibody-secreting plasma cells. In individuals carrying the high-producing promoter haplotype GCC, the post-vaccination antibody titers remain elevated for extended periods, as high IL-10 levels support the survival of long-lived plasma cells in the bone marrow niche [134].

Conversely, genetic variations in the gene encoding the receptor for B-cell activating factor (BAFFR), a TNF receptor superfamily member essential for mature B-cell survival, can reduce receptor expression or binding affinity. Individuals carrying these compromised receptor variants exhibit accelerated decay of neutralizing antibody titers over time, which may compromise long-term protection against high-risk human papillomavirus genotypes. This highlights the importance of the host cytokine-receptor axis in determining the durability of vaccine-induced immunity.

8.2. Cross-Ancestral Disparities in Vaccine Immunogenicity

8.2.1. HLA Distribution Heterogeneity and Population-Level Antibody Titers

The high polymorphism of the human leukocyte antigen complex is a key evolutionary feature of the host immune system, driven by selective pressures to recognize a wide array of pathogens. However, this diversity also results in substantial geographic and ancestral variations in allele frequencies across global populations [135]. Because specific HLA alleles determine the affinity of peptide presentation for vaccine-derived L1 virus-like particles, this global variation in allele frequencies can lead to population-level differences in vaccine immunogenicity.

For instance, the protective HLA-DRB1*04:01 allele, which is associated with robust neutralizing antibody responses to the L1 antigen, is highly prevalent in populations of northern European descent but is found at much lower frequencies in sub-Saharan African cohorts.

Conversely, the susceptible HLA-DRB1*15:01 allele, which can limit $CD4^+$ helper T-cell activation in response to L1 vaccination, is highly prevalent in certain ancestral cohorts from sub-Saharan Africa and south Asia [136]. These populations may exhibit a higher proportion of low-responders who generate lower peak antibody titers following a standard three-dose vaccination series.

This ancestral variation is compounded by the high genetic diversity of human papillomavirus genotypes prevalent in these underrepresented regions. Many current vaccines were designed using antigens derived from genotypes most common in North American and European populations.

If the vaccine-derived L1 epitopes exhibit poor sequence homology with the circulating viral strains in African populations, and this is combined with an unfavorable host HLA background, the real-world effectiveness of the vaccine may be compromised. This highlights the need to incorporate ancestral immunogenetic diversity into the design and evaluation of next-generation multivalent prophylactic vaccines.

9. Pharmaceutical Target Intersection Mapping

9.1. Intersecting Therapeutic Agents and Host-Virus Pathways

9.1.1. Innate Immune Agonists and Downstream Adapter Activation

To clear an established, persistent human papillomavirus infection or drive the regression of pre-cancerous cervical intraepithelial neoplasia, therapeutic interventions must overcome the local immune evasion mechanisms established by the virus. One of the primary pharmacological strategies under active clinical investigation is the application of small-molecule innate immune agonists designed to reactivate silent pattern recognition receptors within the cervical mucosa.

Imiquimod, a synthetic imidazoquinoline amine compound, is a topically applied agonist of Toll-like receptor 7 and 8 (TLR7/8) [137].

The primary mechanism of action of Imiquimod is binding to endosomal TLR7/8 on local keratinocytes and resident dendritic cells, which activates the classical MyD88-dependent signaling pathway.

This signaling cascade triggers the activation of the I-kappa-B kinase (IKK) complex, leading to the nuclear translocation of NF-kappa B and the subsequent transcription of pro-inflammatory cytokines, including IFN-α, TNF-α, and IL-12 [138].

The local release of these cytokines recruits and activates host cytotoxic $CD8^+$ T-lymphocytes and natural killer cells, promoting the targeted elimination of dysplastic cells expressing the viral oncoproteins E6 and E7.

However, the therapeutic efficacy of Imiquimod is influenced by host genetic polymorphisms in downstream signaling adapters. In individuals carrying polymorphisms within the MYD88 promoter or the IRAK gene family that reduce adapter stability, the downstream response to Toll-like receptor activation is attenuated. This results in a decreased localized cytokine response and a

diminished therapeutic effect, showing the clinical value of host pharmacogenomic profiling in guiding targeted therapeutic interventions.

Table 5. Pharmacogenomic and Pharmacological Intersection of HPV Preventive and Therapeutic Interventions

Clinical Intervention	Targeted Biomarker / Protein	Intersecting Host Pathway	Host Genetic / Pharmacogenomic Modifiers	Impact on Therapeutic Efficacy & Immunogenicity	References
Prophylactic Vaccines (Gardasil, Cervarix)	L1 Virus-Like Particles (VLPs)	Humoral Adaptive Immunity & Follicular Helper T-cell (Tfh) priming	HLA-DRB1 (*04:01 / *07:01 vs. *15:01 / *03:01)	High-affinity alleles generate superior peak neutralizing antibody titers and long-term memory; low-affinity alleles show accelerated antibody decay.	[131], [132]
Prophylactic Vaccines (Gardasil, Cervarix)	L1 Virus-Like Particles (VLPs)	Humoral Memory & Class Switching	IL4 (rs2243250) and IL10 (rs1800896) promoter variants	High-producing promoter genotypes stabilize plasma cell survival, increasing the durability of mucosal IgG transudation.	[133], [134]
Topical Innate Immunotherapy (Imiquimod)	TLR7 / TLR8 Receptors	Innate Pattern Recognition & MyD88-dependent Inflammation	MYD88 promoter and IRAK1/IRAK4 complex polymorphisms	Attenuated adapter signaling reduces NF-ϰ B nuclear translocation, leading to a diminished local pro-inflammatory cytokine profile.	[137], [138]
Therapeutic Vaccines (VGX-3100, GTL001)	E6 and E7 Oncoproteins	Antigen Processing & Cytotoxic T-Lymphocyte (CTL) Activation	Classical Class I alleles (HLA-A*02:01, HLA-B supertypes)	Successful presentation of E7{11-20} on high-affinity Class I molecules triggers targeted, immune-mediated cytolysis of dysplastic lesions.	[139], [140]
Small-Molecule Oncoprotein Inhibitors (RITA, pep-11)	E6 / E6AP binding interface	Proteasomal Degradation & Host Tumor Suppressor Safeguards	TP53 rs1042522 (Pro72Arg) and CDKN2A promoter variants	Arg72 carriers require higher drug concentrations to achieve therapeutic p53 accumulation due to rapid baseline degradation kinetics.	[141], [142]

9.1.2. Therapeutic Vaccines and E6/E7 Targeted Antigen Presentation

Prophylactic vaccines rely on the production of neutralizing antibodies to prevent viral entry, whereas therapeutic vaccines are designed to generate a robust cell-mediated immune response to eradicate established, virus-infected cells. These formulations, which are under evaluation in Phase II and Phase III clinical trials, target the viral oncoproteins E6 and E7 because these proteins are continuously expressed in dysplastic and malignant cells.

Therapeutic vaccine platforms include recombinant proteins, peptide-adjuvant formulations, DNA plasmids, and viral vectors (such as VGX-3100, TA-CIN, and GTL001) [139].

The primary mechanism of action of these therapeutics is delivering immunogenic E6 and E7 antigens to local professional antigen-presenting cells, which then migrate to regional lymph nodes to prime tumor-specific $CD8^+$ cytotoxic T-lymphocytes.

The therapeutic efficacy of these vaccines is dependent on the host HLA genetic background. For the primed cytotoxic T-lymphocytes to recognize and destroy the dysplastic keratinocytes, the vaccine-derived E6 and E7 peptides must be presented on classical HLA class I molecules (HLA-A, HLA-B, and HLA-C) expressed on the surface of target cells [140].

In individuals expressing the HLA-A*02:01 allele, specific E7 peptides (such as $E7_{11-20}$ and $E7_{82-90}$) are presented with high binding affinity, inducing a highly targeted and effective cytotoxic T-lymphocyte response.

Conversely, in individuals lacking this allele or expressing alleles with lower affinity for these specific peptide fragments, the therapeutic immune response is limited. To address this immunogenetic limitation, next-generation therapeutic vaccines are being designed to incorporate a wider array of overlapping peptide fragments or poly-epitope cassettes, ensuring broad population coverage regardless of an individual's specific HLA haplotype.

9.1.3. Small-Molecule Inhibitors of Oncogenic Degradation Pathways

In addition to immunotherapeutic strategies, small-molecule inhibitors designed to disrupt the biochemical activity of the viral oncoproteins E6 and E7 represent an active area of drug discovery. The E6 oncoprotein drives cellular transformation by forming a complex with the host ubiquitin ligase E6AP, which targets the tumor suppressor p53 for proteasomal degradation.

Small-molecule inhibitors designed to physically block the interaction between E6 and E6AP (such as RITA and pep-11) can prevent the ubiquitination of p53, restoring physiological levels of the active tumor suppressor within dysplastic cells [141].

This accumulation of active p53 restores the host cell's DNA damage response, leading to the transcription of downstream regulatory genes, such as p21, and triggering cell cycle arrest or programmed cell death.

The therapeutic efficacy of these small-molecule inhibitors is modified by host genetic polymorphisms in the ubiquitin-proteasome pathway and the target tumor suppressor itself. In individuals carrying the susceptible TP53 Arg72 variant, which exhibits higher affinity for E6-mediated degradation, higher concentrations of the inhibitor may be required to achieve therapeutic restoration of p53 levels compared to individuals with the Pro72 variant [142].

Concurrently, polymorphisms in the CDKN2A gene locus, which encodes $p16^{INK4a}$ and $p14^{ARF}$, can influence the cellular response to p53 restoration. If a patient harbors genetic variants that compromise the functional stability of $p14^{ARF}$ (which normally inhibits the p53 negative regulator MDM2), the therapeutic effect of E6-inhibitors may be reduced due to rapid MDM2-mediated degradation. This shows the necessity of analyzing host genetic backgrounds when evaluating small-molecule oncology pipelines.

9.2. Comprehensive Pharmaceutical Target Map

The complicated intersection between host cellular proteins, viral oncoproteins, and current or pipeline pharmacological interventions is represented in the diagram below. The map illustrates how therapeutic agents target specific nodes within the cell, highlighting the relationship between host genetic variations and pharmacological outcomes. The clinical progression of cervical dysplasia is determined by how therapeutic agents interact with this cellular network. Prophylactic vaccines prevent viral entry by generating neutralizing antibodies that block basal cell infection [143].

Once infection is established, innate agonists like Imiquimod stimulate Toll-like receptor signaling to bypass viral immune evasion, and therapeutic vaccines boost T-cell-mediated destruction of dysplastic cells.

At the molecular level, small-molecule inhibitors target E6 and E7 to halt the degradation of p53 and pRb, restoring normal cell cycle controls [144]. This integrated diagram maps the points of pharmacological intervention, showing the clinical value of host-virus immunogenetics.

10. Population Diversity and Global Health

10.1. Genomic Disparities in Underrepresented Populations

The translation of genetic epidemiological research into clinical screening algorithms and targeted therapies is limited by the lack of genomic diversity in existing scientific databases. The vast majority of large-scale genome-wide association studies, multi-omic analyses, and pharmacogenomic evaluations of human papillomavirus persistence have been conducted in cohorts of European and East Asian ancestry [145].

This concentration of research effort creates a genomic disparity that limits the generalizability of findings. This imbalance is particularly concerning given that the global burden of cervical cancer is heavily concentrated in low- and middle-income countries, particularly in sub-Saharan Africa, Latin America, and South-East Asia.

The genetic architecture of populations from these high-burden regions is characterized by extensive genetic diversity, lower levels of linkage disequilibrium, and unique haplotype structures [146]. Consequently, susceptibility loci and polygenic risk scores identified in European cohorts often exhibit a significant loss of predictive accuracy when applied to ancestrally diverse populations.

For instance, the specific HLA class II alleles and single-nucleotide polymorphisms that correlate with viral persistence in European cohorts may not be informative in sub-Saharan African populations, where different high-risk viral genotypes are prevalent and novel host genetic variants exist.

To address these disparities, researchers must design genomic studies that include ancestrally diverse populations, ensuring that emerging precision medicine tools are effective for the communities most affected by this disease.

Adopting a global health perspective requires that the benefits of genomic research and precision medicine are distributed equitably across all populations, regardless of geographic location or socioeconomic status. The development of advanced screening algorithms, polygenic risk scoring systems, and personalized therapeutic interventions must not become a driver of health inequality.

To achieve global health equity, genomic discovery efforts must be accompanied by investments in research infrastructure, capacity building, and clinical training in low- and middle-income countries [147]. Establishing local genotyping platforms, biobanks, and bioinformatics pipelines in these regions allows for the characterization of host genetic susceptibility within the context of local environmental cofactors and circulating viral genotypes.

Ethical rules must guide these collaborative research initiatives to prevent exploitative "parachute science," where samples are collected from developing nations but analyzed exclusively in high-income countries without returning benefits to the donor communities [148]. Collaborative research agreements must prioritize technology transfer, shared authorship, and equitable access to emerging therapeutics.

When analyzing host genetic susceptibility within diverse populations, studies must also evaluate how these genetic risk factors interact with systemic healthcare disparities, including limited access to vaccination and routine screening. Integrating genomic research with public health interventions is essential to ensure that advances in host genetics contribute to the global elimination of cervical cancer.

11. Clinical and Public Health Implications

11.1. Precision Prevention and Risk Stratification

11.1.1. Clinical Implementation of Polygenic Risk Scores in Primary Screening

The clinical utility of host genetic susceptibility data lies in its potential to transform cervical cancer screening from a one-size-fits-all model into a personalized, risk-stratified strategy. In current clinical practice, primary screening is based on high-risk human papillomavirus DNA testing and cytological evaluation, which are performed at fixed chronological intervals.

Clinicians could implement precision prevention by incorporating an individual's polygenic risk score, which quantifies their baseline genetic liability to viral persistence and neoplastic progression [149].

Under this proposed clinical theory, women in the highest decile of the polygenic risk score distribution would be identified as possessing a high genetic liability for persistent infection. These individuals would enter primary screening at an earlier age, receive high-frequency viral DNA testing, and be managed with a lower threshold for colposcopic referral upon detection of low-grade cytological abnormalities [150].

Conversely, women in the lowest decile of the distribution, who carry protective immunogenetic profiles, could be safely managed with extended screening intervals. This targeted approach could optimize resource allocation, reduce the physical and psychological morbidity associated with over-screening and unnecessary diagnostic procedures, and improve the cost-effectiveness of screening programs.

11.1.2. Integration of Host-Virus Multi-Omic Biomarkers

Achieving the highest predictive accuracy for clinical risk stratification requires integrating host genomic data with real-time biomarkers of viral activity and mucosal inflammation. While a polygenic risk score provides a stable measure of baseline genetic susceptibility, it does not capture the dynamic, real-time progression of infection.

To address this, clinical protocols should utilize integrated host-virus multi-omic biomarker panels [151].

These panels combine baseline host genotyping with assays measuring active viral oncogene transcription (such as E6 and E7 messenger RNA assays) and host epigenetic modifications (such as hypermethylation of host CDKN2A or CADM1 promoters).

Characterization of the local mucosal proteome and vaginal metabolome can identify signs of tissue remodeling, vaginal dysbiosis, and chronic inflammation, which are known to facilitate viral persistence. Clinicians can construct comprehensive risk engines by combining these dynamic biomarkers with baseline genetic risk data [152].

These integrated models allow for the precise identification of individuals whose infections are on an active oncogenic trajectory, enabling early therapeutic intervention while avoiding unnecessary procedures for those with transient infections. Translating this multi-omic approach into point-of-care, cost-effective assays is a key priority for the clinical management of cervical neoplasia.



Figure 7. Clinical decision tree for Polygenic Risk Score (PRS)-guided precision prevention and primary screening algorithms.

Baseline DNA is extracted to calculate an individual's cumulative polygenic risk score, incorporating weighted effects (βi) of key replicated risk loci. Patients are stratified into three clinical categories: Low-Risk (Bottom Decile): Eligible for extended 10-year screening intervals; Moderate-Risk (Intermediate Deciles): Managed using standard 5-year screening co-testing schedules; High-Risk (Top Decile): Stratified into intensive preventative screening (2-year cycles with early onset). All stratified groups undergo point-of-care co-testing with host-virus multi-omic biomarker panels (measuring active oncogenic E6/E7 transcription or host DNA methylation) to direct colposcopic referral when active dysplasia is detected.

11.2. Public Health Policy and Vaccine Implementation Strategies

The integration of host genetics and pharmacogenomics into public health policy requires a careful re-evaluation of national vaccination and screening programs. Public health authorities must design vaccine implementation strategies that address both immunological efficacy and the equitable distribution of resources.

Because genetic variations in the HLA-DRB1 and HLA-DQB1 loci modulate the peak antibody titers and long-term durability of prophylactic vaccines, population-level genetic profiling can help identify cohorts at higher risk of accelerated antibody decay [153].

In countries where high-risk HLA haplotypes are highly prevalent, public health policies may need to adapt by recommending modified booster schedules or adopting multivalent vaccine formulations that utilize adjuvants designed to stimulate stronger cell-mediated immunity.

However, these precision public health initiatives must not distract from the primary objective of achieving high coverage with primary vaccination and screening [154]. Prophylactic vaccination remains one of the most effective public health interventions available, and maximizing coverage is essential to establish herd immunity.

Genetic risk stratification should be viewed as a complementary tool to optimize screening intervals and allocate resources within established public health guidelines, rather than as a replacement for broad screening programs. Public health messaging must communicate the value of genetic risk assessment without causing confusion or vaccine hesitancy, ensuring that precision approaches support the global elimination of cervical cancer.

12. Knowledge Gaps

12.1. Research Gaps in Host-Virus Genomics

Despite progress in defining the genetic architecture of human papillomavirus persistence and cervical carcinogenesis, several critical research gaps continue to limit the clinical translation of these findings. First, the biological mechanisms underlying the vast majority of susceptibility loci identified through genome-wide association studies remain uncharacterized. Because most of these variants lie within non-coding regions of the genome, functional studies are needed to determine how they modulate gene expression in primary cervical keratinocytes and resident immune cells.

Second, there is a lack of high-resolution, longitudinal multi-omic datasets that capture the dynamic, molecular interactions between host cells and the virus over time.

Most existing studies rely on cross-sectional designs or single-timepoint measurements, which cannot capture the sequential molecular events that drive the transition from viral entry to persistence, genomic integration, and malignant progression.

Additionally, the role of somatic genetic variation within the developing cervical lesion, and how it interacts with the inherited germline genetic background, remains understudied. Dissecting these germline-somatic interactions is essential to understand the selective pressures that drive clonal expansion and invasive progression. Addressing these gaps will require international collaborations, standardized phenotyping protocols, and investments in longitudinal research cohorts.

12.2. Methodological and Technological Advancements

Overcoming the biological and statistical limitations of current host-virus genomic research requires adopting next-generation sequencing technologies and advanced computational methodologies. The transition from microarray-based genotyping to high-throughput whole-genome sequencing allows for the direct identification of rare and low-frequency genetic variants that may possess large individual effect sizes [155].

Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics provide tools to evaluate the cellular and immunological heterogeneity within the cervical transformation zone at single-cell resolution. These spatial technologies enable researchers to evaluate transcription patterns within the physical tumor microenvironment, mapping the spatial relationships between virus-infected keratinocytes, cytotoxic $CD8^+$ T-lymphocytes, and immunosuppressive regulatory T-cells [156].

To process and integrate these high-dimensional, multi-omic datasets, researchers are using deep learning and artificial intelligence platforms.

Neural network architectures can consolidate genome-wide association data with tissue-specific epigenomic marks, vaginal metagenomic profiles, and clinical registries. This modeling allows for the prediction of patient-specific outcomes and the identification of novel therapeutic targets in silico, accelerating the development of targeted diagnostics and therapeutics.

12.3. Precision Prevention and Clinical Implementation

Translating host-virus genomic insights into clinical workflows requires a structured, multidisciplinary roadmap that bridges basic laboratory discovery, clinical validation, and public health implementation. The first phase of this roadmap must focus on expanding genomic discovery efforts to encompass ancestrally diverse populations, ensuring that susceptibility risk models are calibrated and validated for global use [157].

The second phase requires conducting prospective clinical utility trials to evaluate the safety, efficacy, and cost-effectiveness of genetic risk-stratified screening compared to standard clinical screening protocols.

The third phase involves developing standardized clinical guidelines, provider education programs, and patient counseling materials to support the integration of genomic data into clinical practice [158]. Genetic counselors and clinicians must be trained to interpret polygenic risk scores, communicate risk to patients, and implement personalized screening intervals.

Additionally, public health authorities must evaluate the regulatory, ethical, and legal implications of genetic data integration, ensuring data privacy protections and preventing genetic discrimination. The global oncology community can transition from reactive clinical management to proactive, by following this translational roadmap precision-based prevention, contributing to the global elimination of cervical cancer.

13. Conclusion

Prolonged infection with high-risk human papillomavirus genotypes is established as the primary etiological driver of cervical neoplasia, yet the vast majority of exposures result in transient infections that are cleared by host defenses. This biological flaw shows host genetic susceptibility as a critical mediator of viral persistence and malignant progression. Susceptibility is governed by a highly polygenic host architecture, where inherited variations within the human leukocyte antigen complex, innate pattern recognition receptors, cytokine signaling networks, DNA repair machinery, and cell cycle checkpoints dictate the clinical course of viral exposure. In immunocompromised populations, the pharmacological administration of highly active antiretroviral therapy exerts a profound, though complex, influence on the local mucosal immune environment, altering clearance kinetics and modifying the progression of cervical dysplasia. At the population level, these host-virus interactions are modified by environmental cofactors, including tobacco mutagens and exogenous steroid hormones, which interact with inherited host genetic variations to accelerate genomic instability and epigenetic silencing. Host immunogenetic variants, particularly within the polymorphic HLA class II region, act as key determinants of the immunogenicity and durability of prophylactic vaccines, contributing to population-level variations in protective antibody titers.

References

[1] Hamid MKI, Hasneen S, Lima AK, Shawon SR, Shahriar M, Anjum R. Cervical cancer trends, HPV vaccine utilization, and screening in low- and lower-middle-income countries: An updated review. Ther Adv Vaccines Immunother. 2025;13:25151355251356646.

[2] Baba SK, Alblooshi SSE, Yaqoob R, Behl S, Al Saleem M, Rakha EA, Malik F, Singh M, Macha MA, Akhtar MK, Houry WA, Bhat AA, Al Menhali A, Zheng ZM, Mirza S. Human papilloma virus (HPV) mediated cancers: An insightful update. J Transl Med. 2025;23(1):483.

[3] Jouya S, Shahabinia Z, Mazidimoradi A, Allahqoli L, Salehiniya H, Lee DY. Cervical cancer epidemiology: Global incidence, mortality, survival, risk factors, and equity in HPV screening and vaccination. J Clin Med. 2026;15(3):1079.

[4] Okunade KS, Adejimi AA, John-Olabode SO, Oshodi YA, Oluwole AA. An overview of HPV screening tests to improve access to cervical cancer screening amongst underserved populations: From development to implementation. Risk Manag Healthc Policy. 2022;15:1823-1830.

[5] Wierzbicka M, San Giorgi MRM, Dikkers FG. Transmission and clearance of human papillomavirus infection in the oral cavity and its role in oropharyngeal carcinoma: A review. Rev Med Virol. 2023;33(1):e2337.

[6] Mengistie BA, Aragaw GM, Anteneh TA, Wondie KY, Kassie AT, Abuhay AE, Biset WM, Mulatu GG, Tsega NT. Prevalence and determinants of precancerous cervical lesions among women screened for cervical cancer in Africa: A systematic review and meta-analysis. PLoS One. 2025;20(12):e0338484.

[7] Baasland I, Bjørge T, Engesæter B, Tropé A, Opdahl S. Cervical intraepithelial neoplasia grade 1 and long-term risk of progression and treatment. PLoS One. 2025;20(4):e0320739.

[8] Milano G, Guarducci G, Nante N, Montomoli E, Manini I. Human papillomavirus epidemiology and prevention: Is there still a gender gap? Vaccines. 2023;11(6):1060.

[9] West N, Boz V, Zanotta N, Cason C, Campisciano G, Casuccio A, Gianfrilli D, Fasciana TMA, Capra G, Salfa MC, Sesti F, Suligoi B, Valent F, Brunelli L, Comar M. Human papillomavirus: An old new history. Pathogens. 2025;14(10):1043.

[10] Swai P, Rasch V, Linde DS, Mchome B, Manongi R, Wu CS, Waldstrom M, Iftner T, Mwaiselage J, Kjaer SK. Persistence and risk factors of high-risk human papillomavirus infection among HIV positive and HIV negative Tanzanian women: A cohort study. Infect Agents Cancer. 2022;17(1):26.

[11] Hewavisenti RV, Arena J, Ahlenstiel CL, Sasson SC. Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk. Front Immunol. 2023;14:1112513.

[12] Savage D, Hu J, Burgener AD, Raouf A, Murooka TT. Cell-mediated immunity against human papillomavirus infection: From viral clearance to oncogenesis. Viruses. 2026;18(3):362.

[13] Legaki E, Lappa T, Prasoula KL, Kardasi Z, Kalampokas E, Kalampokas T, Roubelakis MG, Charvalos E, Gazouli M. HPV-driven cervical carcinogenesis: Genetic and epigenetic mechanisms and diagnostic approaches. Int J Mol Sci. 2026;27(2):803.

[14] Espinoza H, Ha KT, Pham TT, Espinoza JL. Genetic predisposition to persistent human papillomavirus infection and virus-induced cancers. Microorganisms. 2021;9(10):2092.

[15] Rembiałkowska N, Rekiel K, Urbanowicz P, Mamala M, Marczuk K, Wojtaszek M, Żywica M, Radzevičiūtė-Valčiukė E, Novickij V, Kulbacka J. Epigenetic dysregulation in cancer: Implications for gene expression and DNA repair-associated pathways. Int J Mol Sci. 2025;26(13):6531.

[16] García-Quiroz J, Vázquez-Almazán B, García-Becerra R, Díaz L, Avila E. The interaction of human papillomavirus infection and prostaglandin E2 signaling in carcinogenesis: A focus on cervical cancer therapeutics. Cells. 2022;11(16):2528.

[17] Schichl K, Doorbar J. Regulation and deregulation of viral gene expression during high-risk HPV infection. Viruses. 2025;17(7):937.

[18] Li J, Li S. From viral infection to genome reshaping: The triggering role of HPV integration in cervical cancer. Int J Mol Sci. 2025;26(18):9214.

[19] Xiao Q, Liu Y, Li T, Wang C, He S, Zhai L, Yang Z, Zhang X, Wu Y, Liu Y. Viral oncogenesis in cancer: From mechanisms to therapeutics. Signal Transduct Target Ther. 2025;10:151.

[20] Castro-Muñoz LJ, Rocha-Zavaleta L, Lizano M, Ramírez-Alcántara KM, Madrid-Marina V, Manzo-Merino J. Alteration of the IFN-pathway by human papillomavirus proteins: Antiviral immune response evasion mechanism. Biomedicines. 2022;10(11):2965.

[21] Roy-Biswas S, Hibma M. The epithelial immune response to human papillomavirus infection. Pathogens. 2025;14(5):464.

[22] Mehrani Y, Morovati S, Keivan F, Tajik T, Forouzanpour D, Shojaei S, Bridle BW, Karimi K. Dendritic cells and their crucial role in modulating innate lymphoid cells for treating and preventing infectious diseases. Pathogens. 2025;14(8):794.

[23] Zhao X, Du R, Rong L. Balancing host defense and viral tolerance for the development of next-generation broad-spectrum antiviral agents. Pathogens. 2025;14(9):911.

[24] Pavelescu LA, Mititelu-Zafiu NL, Mindru DE, Vladareanu R, Curici A. Molecular insights into HPV-driven cervical cancer: Oncoproteins, immune evasion, and epigenetic modifications. Microorganisms. 2025;13(5):1000.

[25] Sisodiya S, Singh P, Joshi T, Aftab M, Firdausi N, Khan A, Mishra N, Jamil Khan N, Tanwar P, Gupta V, Hussain S. Human papillomavirus-mediated cervical cancer: Epigenetic interplay and clinical implications. Front Microbiol. 2025;16:1633283.

[26] Khoshnazar SM, Salarizadeh N, Mohammad-Sadeghipour M, Shahpar A, Izadi M, Behzadnia MJ, Farhadi Khoozani M, Alimohammadi M, Farahani N, Hushmandi K. Molecular interaction of human papillomavirus (HPV) with microRNAs: Insights into the development of cervical cancer and treatment approaches. Infect Agents Cancer. 2025;20(1):49.

[27] Vats A, Trejo-Cerro O, Thomas M, Banks L. Human papillomavirus E6 and E7: What remains? Tumour Virus Res. 2021;11:200213.

[28] Studstill CJ, Mac M, Moody CA. Interplay between the DNA damage response and the life cycle of DNA tumor viruses. Tumour Virus Res. 2023;16:200272.

[29] Nelson CW, Mirabello L. Human papillomavirus genomics: Understanding carcinogenicity. Tumour Virus Res. 2023;15:200258.

[30] Torres MKDS, Pereira Neto GDS, Cayres Vallinoto IMV, Reis LO, Vallinoto ACR. The impact of oncogenic viruses on cancer development: A narrative review. Biology. 2025;14(7):797.

[31] Chapwanya M, Fouape AC, Tsanou B. Within host dynamics of HPV infection with cellular immunity and HPV-infected dormant cells reactivation. Infect Dis Model. 2026;11(3):854-879.

[32] Salauddin M, Bhattacharyya D, Samanta I, Saha S, Xue M, Hossain MG, Zheng C. Role of TLRs as signaling cascades to combat infectious diseases: A review. Cell Mol Life Sci. 2025;82(1):122.

[33] Carroll SL, Pasare C, Barton GM. Control of adaptive immunity by pattern recognition receptors. Immunity. 2024;57(4):632-648.

[34] Kiamba EW, Goodier MR, Clarke E. Immune responses to human papillomavirus infection and vaccination. Front Immunol. 2025;16:1591297.

[35] Kumar M, Yip L, Wang F, Marty SE, Fathman CG. Autoimmune disease: Genetic susceptibility, environmental triggers, and immune dysregulation. Where can we develop therapies? Front Immunol. 2025;16:1626082.

[36] Condrat CE, Cretoiu D, Radoi VE, Mihele DM, Tovaru M, Bordea CI, Voinea SC, Suciu N. Unraveling immunological dynamics: HPV infection in women Insights from pregnancy. Viruses. 2023;15(10):2011.

[37] Dong M, Dong Y, Bai J, Li H, Ma X, Li B, Wang C, Li H, Qi W, Wang Y, Fan A, Han C, Xue F. Interactions between microbiota and cervical epithelial, immune, and mucus barrier. Front Cell Infect Microbiol. 2023;13:1124591.

[38] Quiros-Roldan E, Sottini A, Natali PG, Imberti L. The impact of immune system aging on infectious diseases. Microorganisms. 2024;12(4):775.

[39] Rio P, Caldarelli M, Miccoli E, Guazzarotti G, Gasbarrini A, Gambassi G, Cianci R. Sex differences in immune responses to infectious diseases: The role of genetics, hormones, and aging. Diseases. 2025;13(6):179.

[40] Eslami M, Arjmand N, Mahmoudian F, Babaeizad A, Tahmasebi H, Fattahi F, Oksenych V. Deciphering host–virus interactions and advancing therapeutics for chronic viral infection. Viruses. 2025;17(3):390.

[41] Alanazi A, Ibrahim MN, El Azab EF, Elithy MA. Host cell virus interactions: Molecular mechanisms, immune modulation, viral pathogenesis, and emerging therapeutic targets. Viruses. 2026;18(1):125.

[42] Hoang Nguyen KH, Le NV, Nguyen PH, Nguyen HHT, Hoang DM, Huynh CD. Human immune system: Exploring diversity across individuals and populations. Heliyon. 2025;11(2):e41836.

[43] Hegab Souquette A, Allen EK, Oshansky CM, Rampersaud E, Walker EV, Tang L, Wong SS, Jeevan T, Shi L, Pounds S, Qu JH, Elias G, Kuan G, Balmaseda A, Zapata R, Shaw-Saliba K, Van Damme P, Van Tendeloo V, Dib JC, Thomas PG. Integrated drivers of basal and acute immunity in diverse human populations. Cell Rep Med. 2026;7(4):102690.

[44] La Frazia S, Pauciullo S, Zulian V, Garbuglia AR. Viral oncogenesis: Synergistic role of genome integration and persistence. Viruses. 2024;16(12):1965.

[45] Xue D, Hajat A, Fohner AE. Conceptual frameworks for the integration of genetic and social epidemiology in complex diseases. Glob Epidemiol. 2024;8:100156.

[46] Ogbolu MO, Kozlovszky M. Assessment of HPV knowledge and awareness among students and staff at IBB University, Niger State, Nigeria: Implications for health education and prevention. Healthcare. 2024;12(6):665.

[47] Pruski D, Millert-Kalińska S, Wszołek K, Musiałowicz V, Grabowski JP, Jach R, Muallem MZ, Sehouli J, Przybylski M. Analysis of molecular markers of HPV infection persistence: A narrative review. Cancers. 2026;18(6):981.

[48] Siewchaisakul P, Fann JCY, Chen MK, Hsu CY. Genetic biomarkers associated with dynamic transitions of human papillomavirus infection–precancerous–cancer of cervix for navigating precision prevention. Int J Mol Sci. 2025;26(13):6016.

[49] Chiarella P, Capone P, Sisto R. Contribution of genetic polymorphisms in human health. Int J Environ Res Public Health. 2023;20(2):912.

[50] Kermanshahi AZ, Ebrahimi F, Taherpoor A, Eslami N, Baghi HB. HPV-driven cancers: A looming threat and the potential of CRISPR/Cas9 for targeted therapy. Virol J. 2025;22(1):156.

[51] Omidiran O, Patel A, Usman S, Mhatre I, Abdelhalim H, DeGroat W, Narayanan R, Singh K, Mendhe D, Ahmed Z. GWAS advancements to investigate disease associations and biological mechanisms. Clin Transl Discov. 2024;4(3):e296.

[52] Casaburi G, McCullough R, D'Argenio V. Establishing best practices for clinical GWAS: Tackling imputation and data quality challenges. Int J Mol Sci. 2025;26(13):6397.

[53] Politi C, Roumeliotis S, Tripepi G, Spoto B. Sample size calculation in genetic association studies: A practical approach. Life. 2023;13(1):235.

[54] Wang Y, Liu H, Jiang Z, Xiong J, Lai S, Sun P, Li J, Wang X, Cao C. Genetic and familial high-risk assessment in cervical cancer. TransMed. 2026;1(1):100001.

[55] Jin L, Xu L, Jin H, Zhao S, Jia Y, Li J, Hua J. Accuracy of genomic predictions cross populations with different linkage disequilibrium patterns. Genes. 2024;15(11):1419.

[56] Corpas M, Pius M, Poburennaya M, Guio H, Dwek M, Nagaraj S, Lopez-Correa C, Popejoy A, Fatumo S. Bridging genomics' greatest challenge: The diversity gap. Cell Genom. 2025;5(1):100724.

[57] Matsuzaka Y, Yashiro R. Understanding and therapeutic application of immune response in major histocompatibility complex diversity using multimodal artificial intelligence. BioMedInformatics. 2024;4(3):1835-1864.

[58] Arnaiz-Villena A, Juarez I, Vaquero-Yuste C, Lledo T, Martin-Villa JM, Suarez-Trujillo F. Complex interactions between the human major histocompatibility complex (MHC) and microbiota: Their roles in disease pathogenesis and immune system regulation. Biomedicines. 2024;12(8):1928.

[59] Seifert F, Eisenblätter R, Beckmann J, Schürmann P, Hanel P, Jentschke M, Böhmer G, Strauß HG, Hirchenhain C, Schmidmayr M, Müller F, Fasching P, Luyten A, Häfner N, Dürst M, Runnebaum IB, Hillemanns P, Dörk T, Ramachandran D. Association of two genomic variants with HPV type-specific risk of cervical cancer. Tumour Virus Res. 2023;16:200269.

[60] Naidoo L, Arumugam T, Ramsuran V. Narrative review explaining the role of HLA-A, -B, and -C molecules in COVID-19 disease in and around Africa. Infect Dis Rep. 2024;16(2):380-406.

[61] Ghosh AG, Kim HL, Khor SS. HLA alleles and dengue susceptibility across populations in the era of climate change: A comprehensive review. Front Immunol. 2025;16:1473475.

[62] Medhasi S, Chantratita N. Human leukocyte antigen (HLA) system: Genetics and association with bacterial and viral infections. J Immunol Res. 2022;2022:9710376.

[63] Louvanto K, Baral P, Burchell A, Ramanakumar A, El-Zein M, Tellier PP, Coutlée F, Roger M, Franco EL. Role of human leukocyte antigen allele sharing in human papillomavirus infection transmission among heterosexual couples: Findings from the HITCH cohort study. J Infect Dis. 2022;226(7):1175-1183.

[64] Bharathi G, Bharathi A, Saravana K. Human infectious disease susceptibility: Key perspectives. Egypt J Med Hum Genet. 2026;27(1):3.

[65] Zhou X, Ma J, He L, Li H. Prevalence and genotype distribution of HPV infection among women in Chengdu from 2019 to 2024: A retrospective single-center study. Infect Agents Cancer. 2025;20:68.

[66] Chiarella P, Capone P, Sisto R. Contribution of genetic polymorphisms in human health. Int J Environ Res Public Health. 2023;20(2):912.

[67] Seifert F, Dörk T, Ramachandran D. Host immunogenetics of HPV-associated cervical cancer: A review of the HLA and non-HLA genetic variations. Front Med. 2024;11:1385412.

[68] Legaki E, Gazouli M. Immunogenetic pathways and check point regulators in gynecological malignancies. J Immunol Res. 2025;2025:8829401.

[69] Donniacuo A, Mauro A, Cardamone C, Basile A, Manzo P, Dimitrov J, Cammarota AL, Marzullo L, Triggiani M, Turco MC, De Marco M, Rosati A. Comprehensive profiling of cytokines and growth factors: Pathogenic roles and clinical applications in autoimmune diseases. Int J Mol Sci. 2025;26(18):8921.

[70] Lu FQ, Feng HM, Wang JG, Song KL. Causal relationships between immune cells, inflammatory cytokines, and pertussis: Bidirectional 2-sample Mendelian randomization study and mediation analysis. Medicine. 2024;103(48):e40712.

[71] Donniacuo A, Rosati A. Interleukin-6 signaling pathways in modern oncology. Cytokine Growth Factor Rev. 2025;78:32-45.

[72] Donniacuo A, Mauro A, Rosati A. Comprehensive profiling of cytokines and growth factors. Int J Mol Sci. 2025;26(18):8921.

[73] Rio P, Cianci R. Sex differences in immune responses to infectious diseases. Diseases. 2025;13(6):179.

[74] Rembiałkowska N, Rekiel K, Kulbacka J. Epigenetic dysregulation in cancer: Implications for gene expression and DNA repair-associated pathways. Int J Mol Sci. 2025;26(13):6531.

[75] Lu FQ, Song KL. Causal relationships between immune cells and inflammatory cytokines. Medicine. 2024;103(48):e40712.

[76] Shi Y, Su J, Chen R, Wei W, Yuan Z, Chen X, Wang X, Liang H, Ye L, Jiang J. The role of innate immunity in natural elite controllers of HIV-1 infection. Front Immunol. 2022;13:780922.

[77] Salauddin M, Zheng C. Role of TLRs as signaling cascades to combat infectious diseases: A review. Cell Mol Life Sci. 2025;82(1):122.

[78] Kiamba EW, Clarke E. Immune responses to human papillomavirus infection and vaccination. Front Immunol. 2025;16:1591297.

[79] Carroll SL, Pasare C, Barton GM. Control of adaptive immunity by pattern recognition receptors. Immunity. 2024;57(4):632-648.

[80] Salauddin M, Bhattacharyya D, Samanta I, Saha S, Xue M, Hossain MG, Zheng C. Role of TLRs as signaling cascades to combat infectious diseases: A review. Cell Mol Life Sci. 2025;82(1):122.

[81] Mehrani Y, Karimi K. Dendritic cells and their crucial role in modulating innate lymphoid cells for treating and preventing infectious diseases. Pathogens. 2025;14(8):794.

[82] Zhao X, Rong L. Balancing host defense and viral tolerance for the development of next-generation broad-spectrum antiviral agents. Pathogens. 2025;14(9):911.

[83] Kiamba EW, Goodier MR, Clarke E. Immune responses to human papillomavirus infection and vaccination. Front Immunol. 2025;16:1591297.

[84] Naidoo L, Ramsuran V. Narrative review explaining the role of HLA molecules. Infect Dis Rep. 2024;16(2):380-406.

[85] Seifert F, Dörk T, Ramachandran D. Genomic variants and host immunity in HPV-induced carcinogenesis. Front Oncol. 2024;14:1329103.

[86] Sengupta P, Chattopadhyay S. Interferons in viral infections. Viruses. 2024;16(3):451.

[87] Dalskov L, Gad HH, Hartmann R. Viral recognition and the antiviral interferon response. EMBO J. 2023;42(14):e112907.

[88] Alanazi A, Elithy MA. Host cell virus interactions: Molecular mechanisms and immune modulation. Viruses. 2026;18(1):125.

[89] Eslami M, Oksenych V. Deciphering host–virus interactions and advancing therapeutics for chronic viral infection. Viruses. 2025;17(3):390.

[90] Sengupta P, Chattopadhyay S. Interferons in viral infections. Viruses. 2024;16(3):451.

[91] Dalskov L, Gad HH, Hartmann R. Viral recognition and the antiviral interferon response. EMBO J. 2023;42(14):e112907.

[92] Castro-Muñoz LJ, Manzo-Merino J. Alteration of the IFN-pathway by human papillomavirus proteins. Biomedicines. 2022;10(11):2965.

[93] Alanazi A, Ibrahim MN, Elithy MA. Host cell virus interactions. Viruses. 2026;18(1):125.

[94] Savage D, Murooka TT. Cell-mediated immunity against human papillomavirus infection. Viruses. 2026;18(3):362.

[95] Roy-Biswas S, Hibma M. The epithelial immune response to human papillomavirus infection. Pathogens. 2025;14(5):464.

[96] Chen J, Potlapalli R, Quan H, Chen L, Xie Y, Pouriyeh S, Sakib N, Liu L, Xie Y. Exploring DNA damage and repair mechanisms: A review with computational insights. BioTech. 2024;13(1):3.

[97] Szatkowska M, Zdrada-Nowak J. Genetic polymorphisms in base excision repair (BER) and nucleotide excision repair (NER) pathways as potential biomarkers for gynecological cancers: A comprehensive literature review. Cancers. 2025;17(13):2170.

[98] Benedetti F, Curreli S, Gallo RC, Zella D. Tampering of viruses and bacteria with host DNA repair: Implications for cellular transformation. Cancers. 2021;13(2):241.

[99] Szatkowska M, Zdrada-Nowak J. Genetic polymorphisms in repair pathways as potential biomarkers. Cancers. 2025;17(13):2170.

[100] Papalouka C, Adamaki M, Batsaki P, Zoumpourlis P, Tsintarakis A, Goulielmaki M, Fortis SP, Baxevanis CN, Zoumpourlis V. DNA damage response mechanisms in head and neck cancer: Significant implications for therapy and survival. Int J Mol Sci. 2023;24(3):2760.

[101] Porter VL, Marra MA. The drivers, mechanisms, and consequences of genome instability in HPV-driven cancers. Cancers. 2022;14(19):4623.

[102] Despot A, Fureš R, Despot AM, Hrgović Z, Gredičak M, Malinac Malojčić S, Ćosić V, Mešić L, Sinković N, Sabol I. HPV infection and oxidative stress in cervical carcinogenesis: Linking apoptosis, senescence, SASP, and EMT. Antioxidants. 2026;15(4):486.

[103] Despot A, Sabol I. HPV infection, senescence and apoptosis pathways. Antioxidants. 2026;15(4):486.

[104] Mashkina EV, Volchik VV, Muzlaeva ES, Derevyanchuk EG. Expression of DNA repair and cell cycle control genes in HPV infection. Vavilov J Genet Breed. 2025;29(3):433-439.

[105] Mashkina EV, Derevyanchuk EG. Expression of cell cycle control genes in HPV. Vavilov J Genet Breed. 2025;29(3):433-439.

[106] Despot A, Hrgović Z, Sabol I. HPV infection and oxidative stress in cervical carcinogenesis. Antioxidants. 2026;15(4):486.

[107] Mashkina EV, Volchik VV, Muzlaeva ES, Derevyanchuk EG. Expression of DNA repair and cell cycle control genes in HPV infection. Vavilov J Genet Breed. 2025;29(3):433-439.

[108] Zhao C, Onyino J, Gao X. Current advances in the functional diversity and mechanisms underlying endophyte–plant interactions. Microorganisms. 2024;12(4):779.

[109] Rembiałkowska N, Rekiel K, Urbanowicz P, Mamala M, Marczuk K, Wojtaszek M, Żywica M, Radzevičiūtė-Valčiukė E, Novickij V, Kulbacka J. Epigenetic dysregulation in cancer. Int J Mol Sci. 2025;26(13):6531.

[110] Folliero V, Dell'Annunziata F, Chianese A, Morone MV, Mensitieri F, Di Spirito F, Mollo A, Amato M, Galdiero M, Dal Piaz F, Pagliano P, Rinaldi L, Franci G. Epigenetic and genetic keys to fight HPV-related cancers. Cancers. 2023;15(23):5583.

[111] Kgatle M, Mbambara S, Khoza L, Fadebi O, Mashamba-Thompson T, Sathekge M. The role of pioneering transcription factors, chromatin accessibility and epigenetic reprogramming in oncogenic viruses. Front Microbiol. 2025;16:1602497.

[112] Khoshnazar SM, Salarizadeh N, Mohammad-Sadeghipour M, Shahpar A, Izadi M, Behzadnia MJ, Farhadi Khoozani M, Alimohammadi M, Farahani N, Hushmandi K. Molecular interaction of human papillomavirus (HPV) with microRNAs: Insights into the development of cervical cancer and treatment approaches. Infect Agents Cancer. 2025;20(1):49.

[113] Tomaziu-Todosia Anton E, Anton GI, Scripcariu IS, Dumitraşcu I, Scripcariu DV, Balmus IM, Ionescu C, Visternicu M, Socolov DG. Oxidative stress, inflammation, and antioxidant strategies in cervical cancer A narrative review. Int J Mol Sci. 2025;26(10):4961.

[114] Tomaziu-Todosia Anton E, Socolov DG. Oxidative stress, inflammation, and antioxidant strategies in cervical cancer. Int J Mol Sci. 2025;26(10):4961.

[115] Chen J, Xie Y. Exploring DNA damage and repair mechanisms: A review with computational insights. BioTech. 2024;13(1):3.

[116] Szatkowska M, Zdrada-Nowak J. Genetic polymorphisms in base excision repair (BER) and nucleotide excision repair (NER) pathways. Cancers. 2025;17(13):2170.

[117] Tomaziu-Todosia Anton E, Anton GI, Socolov DG. Hormonal and lifestyle cofactors in cervical carcinogenesis. Int J Mol Sci. 2025;26(10):4961.

[118] Legaki E, Gazouli M. HPV-driven cervical carcinogenesis: Genetic and epigenetic mechanisms. Int J Mol Sci. 2026;27(2):803.

[119] Pavelescu LA, Curici A. Molecular insights into HPV-driven cervical cancer. Microorganisms. 2025;13(5):1000.

[120] Rembiałkowska N, Kulbacka J. Epigenetic dysregulation in cancer: Implications for gene expression and DNA repair-associated pathways. Int J Mol Sci. 2025;26(13):6531.

[121] Głowienka-Stodolak M, Bagińska-Drabiuk K, Szubert S, Hennig EE, Horala A, Dąbrowska M, Micek M, Ciebiera M, Zeber-Lubecka N. Human papillomavirus infections and the role played by cervical and cervico-vaginal microbiota Evidence from next-generation sequencing studies. Cancers. 2024;16(2):399.

[122] Dong M, Xue F. Interactions between microbiota and cervical epithelial, immune, and mucus barrier. Front Cell Infect Microbiol. 2023;13:1124591.

[123] Głowienka-Stodolak M, Zeber-Lubecka N. Human papillomavirus infections and the role played by cervical and cervico-vaginal microbiota. Cancers. 2024;16(2):399.

[124] Gonçalves MG, Ferreira MT, López RVM, Ferreira S, Sirak B, Baggio ML, Lazcano-Ponce E, Nyitray AG, Giuliano AR, Villa LL, Sichero L. Prevalence and persistence of HPV-16 molecular variants in the anal canal of men: The HIM study. J Clin Virol. 2022;149:105128.

[125] Nyide B, Thomas M, Banks L, Mkhize PP, Matume ND. Genetic diversity of selected high-risk HPV types prevalent in Africa and not covered by current vaccines: A pooled sequence data analysis. Int J Mol Sci. 2025;26(22):11056.

[126] Chapwanya M, Tsanou B. Within host dynamics of HPV infection with cellular immunity. Infectious Disease Modelling. 2026;11(3):854-879.

[127] Salauddin M, Zheng C. Role of TLRs as signaling cascades. Cell Mol Life Sci. 2025;82(1):122.

[128] Motsinger-Reif AA, Woychik R. Gene–environment interactions within a precision environmental health framework. Cell Genom. 2024;4(7):100591.

[129] Hegab Souquette A, Thomas PG. Integrated drivers of basal and acute immunity in diverse human populations. Cell Rep Med. 2026;7(4):102690.

[130] Cangelosi G, Sacchini F, Mancin S, Petrelli F, Amendola A, Fappani C, Sguanci M, Morales Palomares S, Gravante F, Caggianelli G. Papillomavirus vaccination programs and knowledge gaps as barriers to implementation: A systematic review. Vaccines. 2025;13(5):460.

[131] Kiamba EW, Clarke E. Immune responses to human papillomavirus infection and vaccination. Front Immunol. 2025;16:1591297.

[132] Seifert F, Dörk T, Ramachandran D. Host immunogenetics of HPV-associated cervical cancer. Front Med. 2024;11:1385412.

[133] Donniacuo A, Rosati A. Comprehensive profiling of cytokines and growth factors. Int J Mol Sci. 2025;26(18):8921.

[134] Rio P, Cianci R. Sex differences in immune responses. Diseases. 2025;13(6):179.

[135] Wang Y, Martin AR. Aspiring toward equitable benefits from genomic advances to individuals of ancestrally diverse backgrounds. Am J Hum Genet. 2024;111(5):809-824.

[136] Nyide B, Matume ND. Genetic diversity of selected high-risk HPV types prevalent in Africa. Int J Mol Sci. 2025;26(22):11056.

[137] Salauddin M, Zheng C. Role of TLRs as signaling cascades to combat infectious diseases. Cell Mol Life Sci. 2025;82(1):122.

[138] Kiamba EW, Goodier MR, Clarke E. Immune responses to human papillomavirus. Front Immunol. 2025;16:1591297.

[139] Kermanshahi AZ, Baghi HB. HPV-driven cancers: A looming threat and the potential of CRISPR/Cas9 for targeted therapy. Virol J. 2025;22(1):156.

[140] Seifert F, Dörk T, Ramachandran D. Genomic variants and host immunity in HPV-induced carcinogenesis. Front Oncol. 2024;14:1329103.

[141] Sisodiya S, Hussain S. Human papillomavirus-mediated cervical cancer: Epigenetic interplay. Front Microbiol. 2025;16:1633283.

[142] Despot A, Sabol I. HPV infection and oxidative stress in cervical carcinogenesis. Antioxidants. 2026;15(4):486.

[143] Cangelosi G, Caggianelli G. Papillomavirus vaccination programs and knowledge gaps as barriers to implementation. Vaccines. 2025;13(5):460.

[144] Legaki E, Gazouli M. HPV-driven cervical carcinogenesis: Genetic and epigenetic mechanisms and diagnostic approaches. Int J Mol Sci. 2026;27(2):803.

[145] Wang Y, Martin AR. Aspiring toward equitable benefits from genomic advances. Am J Hum Genet. 2024;111(5):809-824.

[146] Corpas M, Fatumo S. Bridging genomics' greatest challenge: The diversity gap. Cell Genom. 2025;5(1):100724.

[147] Edvardsson M, Heenkenda MK. Precision medicine: Personalizing healthcare by bridging aging, genetics, and global diversity. Healthcare. 2025;13(13):1529.

[148] Jouya S, Lee DY. Cervical cancer epidemiology: Global equity in HPV screening and vaccination. J Clin Med. 2026;15(3):1079.

[149] Nguyen HHK, Le HM, Le TQ, Dinh NTQ, Nguyen TT, Nguyen PA, Hoang DM, Huynh CD. Polygenic risk scores: Navigating the future of precision medicine through economic, ethical, and scientific advancements. iScience. 2026;29(1):114375.

[150] Xia C, Xu Y, Li H, He S, Chen W. Benefits and harms of polygenic risk scores in organised cancer screening programmes: A cost-effectiveness analysis. Lancet Reg Health West Pac. 2024;44:101012.

[151] Gisca T, Matasariu DR, Ursache A, Socolov DG, Scripcariu IS, Fudulu A, Anton ETT, Botezatu A. Integrating biomarkers into cervical cancer screening Advances in diagnosis and risk prediction: A narrative review. Diagnostics. 2025;15(24):3231.

[152] Kamzayeva N, Bapayeva G, Terzic M, Primbetov B, Imankulova B, Kim Y, Sultanova A, Kongrtay K, Kadroldinova N, Ukybassova T. Enhancing cervical cancer screening: New diagnostic methodologies, triage, and risk stratification in prevention and treatment. Life. 2025;15(3):367.

[153] Nguyen HHK, Huynh CD. Polygenic risk scores: Navigating the future of precision medicine. iScience. 2026;29(1):114375.

[154] Galani A, Zikopoulos A, Moustakli E, Potiris A, Paraskevaidi M, Arkoulis I, Machairoudias P, Stavrakaki SM, Kyrgiou M, Stavros S. Cervical cancer screening in the HPV-vaccinated and digital era: Reassessing strategies in light of artificial intelligence and evolving risk. Cancers. 2025;17(19):3179.

[155] Kerner G, Kamitaki N, Strober B, Price A. Mapping disease loci to biological processes via joint pleiotropic and epigenomic partitioning. Cell Genom. 2026;6(4):101138.

[156] Zolfi E, Khaleghi Mehr F, Emtiazi N, Moradi Y. A review of the carcinogenic potential of human papillomavirus (HPV) in urological cancers. Virol J. 2025;22(1):53.

[157] Omidiran O, Ahmed Z. GWAS advancements to investigate disease associations. Clin Transl Discov. 2024;4(3):e296.

[158] Karnik M, Tulimilli SV, Anantharaju PG, Bettadapura ADS, Natraj SM, Mohideen HS, Dovat S, Sharma A, Madhunapantula SV. An overview of the mechanisms of HPV-induced cervical cancer. Cancers. 2026;18(2):318.